CHIR-99021 (CT99021) HCl

Catalog No.S2924

Molecular Weight(MW): 501.8

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.

Cited by 111 Publications

Cell Stem Cell, 2019, 24(5):802-811

PubMed: 30880024 ( click the link to review the publication )

Cell, 2018, 174(2):406-421

PubMed: 29887375 ( click the link to review the publication )

Cell, 2018, 174(2):391-405

PubMed: 29937225 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(5):720-731

PubMed: 28343982 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):518-532

PubMed: 28017796 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14413

PubMed: 25945737 ( click the link to review the publication )

Cell Stem Cell, 2015, 10.1016/j.stem.2015.04.020

PubMed: ( click the link to review the publication )

Nat Biotechnol, 2014, 32(11):1121-33

PubMed: 25211370 ( click the link to review the publication )

Nature, 2013, 500(7461):222-6

PubMed: 23812591 ( click the link to review the publication )

Blood, 2019, blood.2019001037

PubMed: 31570489 ( click the link to review the publication )

Nat Commun, 2019, 10(1):928

PubMed: 30804331 ( click the link to review the publication )

Dev Cell, 2019, 50(2):212-228.e6

PubMed: 31178404 ( click the link to review the publication )

Cell Syst, 2019, 8(5):427-445

PubMed: 31078527 ( click the link to review the publication )

Int J Cancer, 2019, 144(2):389-401

PubMed: 29978469 ( click the link to review the publication )

Oncogene, 2019, 38(15):2788-2799

PubMed: 30542117 ( click the link to review the publication )

Mol Metab, 2019, 24:80-97

PubMed: 30930126 ( click the link to review the publication )

PLoS Pathog, 2019, 15(3):e1007667

PubMed: 30901352 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0605

PubMed: 31395667 ( click the link to review the publication )

Front Neurosci, 2019, 13:867

PubMed: 31551670 ( click the link to review the publication )

Front Physiol, 2019, 10:818

PubMed: 31316396 ( click the link to review the publication )

Cell Cycle, 2019, 18(19):2495-2508

PubMed: 31411525 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):5440-5452

PubMed: 31059099 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )
Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Cell Rep, 2018, 25(7):1966-1981.e4

PubMed: 30428361 ( click the link to review the publication )

Cell Rep, 2018, 25(9):2563-2576

PubMed: 30485820 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):22

PubMed: 29426364 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):598

PubMed: 29789524 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(9):1095-1106

PubMed: 30251630 ( click the link to review the publication )

Dig Dis Sci, 2018, 63(10):2604-2616

PubMed: 29948558 ( click the link to review the publication )

Biol Open, 2018, 7(9)

PubMed: 30135081 ( click the link to review the publication )

Methods Mol Biol, 2018, 1649:473-488

PubMed: 29130217 ( click the link to review the publication )

Curr Protoc Hum Genet, 2018, 10.1002/cphg.64

PubMed: 29979824 ( click the link to review the publication )

Methods Mol Biol, 2018, 1733:127-136

PubMed: 29435928 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(31):25929-25940

PubMed: 28718622 ( click the link to review the publication )

Biomater Sci, 2017, 5(8):1567-1578

PubMed: 28715029 ( click the link to review the publication )

Stem Cell Res Ther, 2017, 8(1):156

PubMed: 28676082 ( click the link to review the publication )

Sci Rep, 2017, 7(1):9490

PubMed: 28842634 ( click the link to review the publication )

Biofabrication, 2017, 9(2):025007

PubMed: 28287080 ( click the link to review the publication )

JCI Insight, 2017, 2(18)

PubMed: 28931764 ( click the link to review the publication )

Stem Cells, 2016, 34(7):1765-75

PubMed: 26946228 ( click the link to review the publication )

Sci Rep, 2016, 6:23817

PubMed: 27026509 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0161508

PubMed: 27560518 ( click the link to review the publication )

Exp Ther Med, 2016, 12(6):3851-3858

PubMed: 28101169 ( click the link to review the publication )

Methods Mol Biol, 2016, 1353:181-90

PubMed: 25523811 ( click the link to review the publication )

Methods Mol Biol, 2016, 1480:153-65

PubMed: 27659983 ( click the link to review the publication )
Nat Commun, 2015, 6:7413

PubMed: 26172574 ( click the link to review the publication )

Dev Cell, 2015, 32(6):667-77

PubMed: 25805134 ( click the link to review the publication )

Stem Cell Res, 2015, 10.1016/j.scr.2015.05.004

PubMed: ( click the link to review the publication )

Stem Cells, 2015, 33(3):686-98

PubMed: ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Mol Neurobiol, 2015, 10.1007/s12035-014-9084-z

PubMed: 25663198 ( click the link to review the publication )

J Thromb Haemost, 2015, 10.1111/jth.12954

PubMed: 25858425 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Stem Cells Dev, 2015, 10.1089/scd.2014.0422

PubMed: 25751301 ( click the link to review the publication )

Cell Transplant, 2015, 10.3727/096368914X685762

PubMed: 25562386 ( click the link to review the publication )

Biol Open, 2015, 4(1):48-61

PubMed: ( click the link to review the publication )

J Physiol, 2015, 593(5):1147-57

PubMed: ( click the link to review the publication )

Sci Rep, 2015, 5:9718

PubMed: 25864432 ( click the link to review the publication )

Methods Mol Biol, 2015, 10.1007/7651_2015_220

PubMed: 25762297 ( click the link to review the publication )

Methods Mol Biol, 2015, 1264:453-63

PubMed: 25631034 ( click the link to review the publication )

Cell Biology International Reports, 2015, 10.1002/cbi3.10019

PubMed: ( click the link to review the publication )

Circ Res, 2014, 115(6):556-66

PubMed: 25015077 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(12):4484-9

PubMed: 24623855 ( click the link to review the publication )

Biomaterials, 2014, 35(5):1367-77

PubMed: 24268663 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(4):594-605

PubMed: 25358788 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Acta Biomater, 2014, 10(2):604-12

PubMed: 24200714 ( click the link to review the publication )
Protein Cell, 2014, 5(1):59-68

PubMed: 24474197 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):812-22

PubMed: 24552772 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(4):990-1007

PubMed: 24482122 ( click the link to review the publication )

J Biol Chem, 2014, 289(47):32628-38

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 10.1074/jbc.M114.580076

PubMed: 25301940 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14341-50

PubMed: 24692544 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):724-735

PubMed: ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Stem Cells Dev, 2014, 10.1089/scd.2014.0011

PubMed: 24805295 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Exp Cell Res, 2014, 328(2):351-60

PubMed: 25172557 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115854

PubMed: 25541965 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85089

PubMed: 24465482 ( click the link to review the publication )

PLoS One, 2014, 9(4):e92304

PubMed: 24743237 ( click the link to review the publication )

Exp Biol Med, 2014, 239(10):1390-402

PubMed: 24951472 ( click the link to review the publication )

Theriogenology, 2014, 82(2):283-93

PubMed: 24853281 ( click the link to review the publication )

Cell Reprogram, 2014, 10.1089/cell.2014.0028

PubMed: 25084370 ( click the link to review the publication )

J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2):151-6

PubMed: 24710923 ( click the link to review the publication )

University of GOTHENBURG, 2014, 5495

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:6425

PubMed: 25236849 ( click the link to review the publication )

Methods Mol Biol, 2014, 10.1007/7651_2014_172

PubMed: 25520292 ( click the link to review the publication )

Nat Commun, 2013, 4:2628

PubMed: 24165455 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(52):E5039-48

PubMed: 24248365 ( click the link to review the publication )
Stem Cell Res, 2013, 12(2):364-375

PubMed: 24365601 ( click the link to review the publication )

Stem Cell Rep, 2013, 1(4):360-10

PubMed: 24319670 ( click the link to review the publication )

Antioxid Redox Sign, 2013, 20(18):2907-22

PubMed: 24219064 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):454-67

PubMed: 24282277 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(8):4102-16

PubMed: 23628704 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35500-10

PubMed: 24165128 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1329-40

PubMed: 23867056 ( click the link to review the publication )

Nat Protoc, 2012, 8(1):162-75

PubMed: 23257984 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(27):E1848-57

PubMed: 22645348 ( click the link to review the publication )

Stem Cells, 2012, 30(9):1863-74

PubMed: 22761013 ( click the link to review the publication )

Carcinogenesis, 2012, 33(3):529-37

PubMed: 22201186 ( click the link to review the publication )

J Biol Chem, 2012, 287(2):893-904

PubMed: 22102280 ( click the link to review the publication )

PLoS One, 2012, 7(10):e47312

PubMed: 23077590 ( click the link to review the publication )

BMC Dev Biol, 2012, 12:21

PubMed: 22846383 ( click the link to review the publication )

Bachelor of Science, 2012, East China Normal University

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description

Targets

GSK-3β ^[1] (Cell-free assay)	GSK-3α ^[1] (Cell-free assay)
6.7 nM	10 nM

In vitro

CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM. ^[1] In addition to simulating the actions of insulin, inhibition of GSK-3 by CHIR-99021 (3 μM) increases free cytosolic β-catenin by 1.9-fold, mimicking the canonical Wnt signaling pathway in 3T3-L1 preadipocytes. During any of the first 3 days of differentiation, CHIR-99021 treatment inhibits the preadipocyte differentiation with IC50 of 0.3 μM by blocking induction of CCAAT/enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ). ^[2] Unlike lithium chloride and AR-A014418, CHIR-99021 treatment does not reduce the viability of INS-1E cells even at high concentrations. Instead, CHIR-99021 robustly increases the rate of proliferation of INS-1E cells in a dose-dependent manner, and significantly inhibits INS-E cell death induced by high glucose and high palmitate in a concentration-dependent manner. CHIR-99021 promotes primary beta cell replication in isolated rat islets at concentrations as low as 1 μM, with 2-3 fold increase of cell replication at 5 μM of CHIR-99021 treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
3T3-L1	MYrGeY5kfGmxbjDBd5NigQ>?	MX6zJO69VQ>?	NFnYRWE1KGh?	MUXEUXNQ	M1TLXWlvcGmkaYTzJJBz\WGmaYDvZ5l1\SCmaX\m[ZJmdnSrYYTpc44>	MWqxNlA2PTJyMB?=
insulin receptor–expressing CHO-IR	NFe0UW5HfW6ldHnvckBCe3OjeR?=	Mmf4OVAxKG6P	NF7wU5c{OCCvaX6=	MYjEUXNQ	NH;xZXZC[3SrdnH0[ZMhT2y7Y3;n[Y4hW3mwdHjhd4UhMEeVKR?=	MV2xNlYxPjR7Nx?=
H4IIE	NIrpcnVHfW6ldHnvckBCe3OjeR?=	M2Pje\|ExKM7:TR?=	M{fNNVI1KGh?	NF;ofoVFVVOR	NIL2U5lT\We3bHH0[ZMh\|rJvY3H0[Y5qdiCjY4Tpeol1gSCjbnSgWGlTTSClb370ZYlvcW6pIIDyc41wfGW{IHHjeIl3cXS7	NEDY[owyPTN3MEG5OS=>
Oct4/Sox2/Klf4-infected MEFs	NX;YUItMTnWwY4Tpc44hSXO\|YYm=	MofGNVAh\|ryP	NYPrbG5OOjhiZB?=	MWDEUXNQ	NGPUTYNRem:vb4Tld{BOTU[\|IILldJJw\3KjbX3pcochXHKjboPkeYNm\CCkeTDPZ5Q1NCCVb4iyMEBidmRiS3zmOC=>	NGnISFMyQTh\|OUC1OS=>
Sca-1+ HPC	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHztb44zKM7:TR?=	MY[2JIQ>	MWnEUXNQ	MVXTfY5memerc4TpZ4FtdHlicILvcY91\XNiU3PhMVEsyqCKUFOgdJJwdGmoZYLheIlwdiCjbnSgZ49td267IH\vdo1ifGmxbjD0c4dmfGincjD3bZRpKEWJRh?=	M2Oyb\|IyPjJ2M{S4
HMC1.2	Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKzNEDPxE1?	MUG3NkBp	NFXwXlFFVVOR	MkPJVoVlfWOnczDj[YxtKHO3co\peoFt	Mn\3NlIxOzl\|MEG=
Endothelial cell(EC)	NEHuVZJHfW6ldHnvckBCe3OjeR?=	M1m2WVMh\|ryP		M{Xa[2ROW09?	MX7Qdo9ud3SnczDlcoRwfGinbHnhcEBk\WyuIDjFR{kh\GmoZnXy[Y51cWG2aX;u	NULuXnpwOjJyNUKwNFY>
PANC1	NEHySnVCeG:ydH;zbZMhSXO\|YYm=	MnuyxsA2KM7:TR?=	MnKwO\|IhcA>?	M{XIN2ROW09?	MUPUdolo\2W{czDhckBieG:ydH;0bYMhemW\|cH;ud4U>	M2Gx[lIzOjBzMUi2
INS-1E	NYq2U3N3TnWwY4Tpc44hSXO\|YYm=	Mk\KNk42KM7:TR?=	MUGyOEBp	MkPYSG1UVw>?	NYrwPWFLUW6mdXPld{BiKHKnZIXjeIlwdiCxZjDOVFEhd3[ncnX4dJJme3Orb36=	NWq3OW1IOjJ2Mke3NFQ>
hiPSC-NPs	NEj1Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUSz5qCK\|ryP	NEnQOXA4OiCq	NH7zdoRFVVOR	NUe1e\|JqUW6lcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdsLi	NYjicoRvOjJ4NEK2PFc>
platelets	NXHOSVhuTnWwY4Tpc44hSXO\|YYm=	NI\NWlIyOCEQvF2=	NWWyPHZnOTVibXnu	MV\EUXNQ	MXrJcoNz\WG\|ZYOgeIhzd22kaX6tcYVlcWG2ZXSgdIxifGWuZYSgZYdoemWpYYTpc44h[W6mIFHUVEB{\WO{ZYTpc44>	MVOyN\|I{QTh5Nx?=
DN3	M{nhc2Z2dmO2aX;uJGF{e2G7	Mm\NNVAh\|ryP	Ml73PVYhcA>?	M{H3N2ROW09?	Mn\oTY5kemWjc3XzJINmdGxiZHX2[YxweG2nboSgZY5lKHC{b3zp[oVz[XSrb36=	NIjnb2IzOzV{Nkm4PS=>
embryonic stem cells (ESC)	M2TVfGZ2dmO2aX;uJGF{e2G7	MYWzJOK2VQ>?	M1TzcFEyKGR?	NETxRmtFVVOR	MojQVJJwdW:2ZYOgd4Vt\i2{ZX7le4FtKG:oIH7hx893\S22eYDlJI1wfXOnIHXtZpJ6d26rYzDzeIVuKGOnbHzzJEhGW0Nr	MXuyN\|g1OzNzMh?=
H460	M1m4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;zOUDDvU1?	NULM[llbOjRiaB?=	NWDkOmpJTE2VTx?=	Mkj2VJJwdW:2ZYOgZ4VtdCCycn;sbYZmemG2aX;u	NGX1cmIzPDN4N{[4PC=>
H157	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrWRXQ2KML3TR?=	MXKyOEBp	NULaTpdiTE2VTx?=	MUfQdo9ud3SnczDj[YxtKHC{b3zp[oVz[XSrb36=	NIO3eHczPDN4N{[4PC=>
H460	M3uyPWFxd3C2b4Ppd{BCe3OjeR?=	NU[4cI15PSEEtV2=	MYGyOEBp	MVrEUXNQ	MnvURZR1\W63YYTld{Bk\WyuIHHwc5B1d3Orcx?=	NHrOblQzPDN4N{[4PC=>
H157	NGrHZZVCeG:ydH;zbZMhSXO\|YYm=	M33pS\|UhyrWP	MkCyNlQhcA>?	NY\QUmdkTE2VTx?=	M2XQNWRw\XNibn;0JJNq\26rZnnjZY51dHliYX\m[YN1KGGyb4D0c5Nqew>?	MVSyOFM3PzZ6OB?=
A549	NUfOUphkSXCxcITvd4l{KEG\|c3H5	M4OyZlUhyrWP	NVfQRnNxOjRiaB?=	MkLaSG1UVw>?	NHzS[pVKdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYO=	Mo\hNlQ{Pjd4OEi=
Neural progenitor cells	NWDx[XhqTnWwY4Tpc44hSXO\|YYm=	NWnTe\|lXOyEQvF2=	MUWxNEBl	NYPQbmd6TE2VTx?=	M1nqT2lv\HWlZYOg[4Vv\XKjdHnvckBw\iCwZYXyZYwheHKxZ3XubZRweiClZXzsdy=>	Mnu0NlQ3OzhyM{S=
ES-D3	MnvZR5l1d3SxeHnjJGF{e2G7	MV2xNOKh\|ryP	M3uyVlMh\A>?	NXrBTZVOTE2VTx?=	MVTJcoR2[2W\|IH3v[IVz[XSnIHP5eI91d3irY3n0fUB4cXSqIFnDOVAhd2ZiND65JO69VQ>?	MmrxNlQ4Pzl\|NkW=
ES-CCE	M4PXVmN6fG:2b4jpZ{BCe3OjeR?=	MmT1NVDDqM7:TR?=	NI\DN2M{KGR?	MUnEUXNQ	MoHaTY5lfWOnczDtc4RmemG2ZTDjfZRwfG:6aXPpeJk>	M2PORVI1Pzd7M{[1
ES-D3	MmfWSpVv[3Srb36gRZN{[Xl?	NHLrVHg2yqEQvF2=	M4\OPVMh\A>?	MXrEUXNQ	MYrTeJJwdmeueTDpcoR2[2W\|IITo[UBi[3Srdnn0fUBw\iCZboSvZoV1[S2lYYTlcolvKHCjdHj3ZZk>	NHLVXW0zPDd5OUO2OS=>
ES-CCE	NVrYXllGTnWwY4Tpc44hSXO\|YYm=	MnH3OeKh\|ryP	NEXHeYY{KGR?	M3;ueGROW09?	NXP6V3RTW3S{b37ncJkhcW6mdXPld{B1cGViYXP0bZZqfHlib3[gW451N2KndHGtZ4F1\W6rbjDwZZRpf2G7	MVWyOFc4QTN4NR?=
SW982	NGr5UYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwMkG0NVYh\|ryP	NHHINY1USU6JRWK=
GCT	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2O4[GlEPTB;MD6zNFY4OiEQvF2=	NVjZUHk5W0GQR1XS
769-P	NECwZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknlTWM2OD1yLkW4OFk6KM7:TR?=	M{K5UHNCVkeHUh?=
LOXIMVI	M2G5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;Q[HRKSzVyPUCuOVg5OzJizszN	NV\oNpFRW0GQR1XS
D-336MG	NFnueXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwOES2NkDPxE1?	NGHRdpdUSU6JRWK=
S-117	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnK5TWM2OD1yLkmyNVMyKM7:TR?=	M2[3SnNCVkeHUh?=
D-247MG	NFHrZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwOUS4OVIh\|ryP	NUjkOZdzW0GQR1XS
TYK-nu	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XXZmlEPTB;MT6wO\|kyOiEQvF2=	M{DD[3NCVkeHUh?=
A498	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzjTWM2OD1zLkOwOFY6KM7:TR?=	M{HjbHNCVkeHUh?=
BCPAP	NFuyPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X5WWlEPTB;MT62Olg6QCEQvF2=	MYfTRW5ITVJ?
KYSE-180	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LuWGlEPTB;MT63Nlc5QCEQvF2=	NIjBN\|FUSU6JRWK=
MIA-PaCa-2	NYTzdZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4WzbGlEPTB;MT63OVk4PyEQvF2=	MoXsV2FPT0WU
HCC1395	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIC2b41KSzVyPUGuO\|gzPzNizszN	MlXJV2FPT0WU
RS4-11	M2C3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTFwOUW0NVUh\|ryP	NX[3NmppW0GQR1XS
NCI-H2122	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrSSGNvUUN3ME2yMlI4Pjh2IN88US=>	MoC1V2FPT0WU
SNU-423	NHTxV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHC[VBKSzVyPUKuOFk4QDdizszN	MVrTRW5ITVJ?
SK-LMS-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoH2TWM2OD1{Lk[0NVI5KM7:TR?=	MkTxV2FPT0WU
RPMI-7951	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrhVoluUUN3ME2yMlcxOTl\|IN88US=>	MVrTRW5ITVJ?
COLO-829	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTJwN{[1OEDPxE1?	NXHjSFBHW0GQR1XS
SCC-9	NXvZXYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn35TWM2OD1{Lkm1OFg2KM7:TR?=	MVzTRW5ITVJ?
A704	NX3wb3lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HaeWlEPTB;Mz6wPFEzKM7:TR?=	Mmj5V2FPT0WU
HOP-62	MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;4O2tKSzVyPUOuN\|YxPTRizszN	Mmj1V2FPT0WU
HCC1569	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHOU49NUUN3ME2zMlQ5OzB3IN88US=>	MWXTRW5ITVJ?
A172	NV3LbmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2ThOWlEPTB;Mz63OVQ6QCEQvF2=	MXfTRW5ITVJ?
MOLT-16	M1rqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDoT3NKSzVyPUOuPFg2PTZizszN	MmLkV2FPT0WU
TE-15	NYjrc3hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTNwOUWzOFMh\|ryP	Mn7uV2FPT0WU
OE19	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHoUoRKSzVyPUOuPVY1PTFizszN	NWPlVW1OW0GQR1XS
MHH-ES-1	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fCXWlEPTB;ND6wOFU1PSEQvF2=	NVfEWXp1W0GQR1XS
NKM-1	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rJTGlEPTB;ND6xN\|k4OSEQvF2=	M{SyWnNCVkeHUh?=
RCC10RGB	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37LZ2lEPTB;ND6yPVQ4QSEQvF2=	M{[4SHNCVkeHUh?=
BxPC-3	M2LINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHC[pVGUUN3ME20MlcxOzlzIN88US=>	MYLTRW5ITVJ?
ALL-PO	NI\NNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXNTWM2OD12LkizPFU5KM7:TR?=	NFPUWZZUSU6JRWK=
SK-OV-3	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXSfoNKSzVyPUSuPVk{PCEQvF2=	M3HZVnNCVkeHUh?=
SW1710	M4DyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTVwNEK0OVYh\|ryP	NFPJRnRUSU6JRWK=
NCI-H2452	NHrnTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF33XFJKSzVyPUWuOFU3OjhizszN	MYrTRW5ITVJ?
D-392MG	M3i3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHhfWRxUUN3ME21MlQ6OTR3IN88US=>	NHLJcZVUSU6JRWK=
LB2518-MEL	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUL1dGFjUUN3ME21MlczPjJ5IN88US=>	MmDFV2FPT0WU
BL-41	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\TTHFLUUN3ME21MlgyOjZ4IN88US=>	MWHTRW5ITVJ?
WM-115	NFrnNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTVwOEG1NFkh\|ryP	NWXXVJpuW0GQR1XS
SK-MEL-2	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2T5XGlEPTB;Nj6zPFM1PCEQvF2=	NVrheIljW0GQR1XS
CGTH-W-1	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\PcmJ5UUN3ME22MlQyPyEQvF2=	M{DYc3NCVkeHUh?=
BB65-RCC	NH\2N2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn:0TWM2OD14LkWzNVk2KM7:TR?=	NUDab5pLW0GQR1XS
CAL-85-1	M3LRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33TSmlEPTB;Nj62NFk{PiEQvF2=	M4PzcHNCVkeHUh?=
RT-112	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfOTWM2OD15LkG2OFU3KM7:TR?=	NVHsNXJZW0GQR1XS
MC116	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETBeo5KSzVyPUeuNlg3QTFizszN	M2CwNnNCVkeHUh?=
G-361	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;ne\|dKSzVyPUeuOFY2PjFizszN	NELP[W9USU6JRWK=
SW1417	NXXJNpA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTdwNkS1PFQh\|ryP	MVPTRW5ITVJ?
MV-4-11	Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPvTWM2OD16LkW0N\|A1KM7:TR?=	MojZV2FPT0WU
CAL-72	NE\CR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRThwN{[xNVMh\|ryP	NF2zVldUSU6JRWK=
MKN28	NVrTZVN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDpeIJmUUN3ME24Mlg5PTF4IN88US=>	NHz3e4xUSU6JRWK=
MEG-01	NUL5TZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPOdlZKSzVyPUiuPVkxPDNizszN	MnTMV2FPT0WU
ACHN	M2izbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\wVmlEPTB;OT6zNFU1PiEQvF2=	MojzV2FPT0WU
NCI-H1755	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTlwM{m5PFYh\|ryP	NH7Ve5BUSU6JRWK=
NCI-H64	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjDcFdsUUN3ME25MlQzOjV3IN88US=>	M2nLO3NCVkeHUh?=
COLO-205	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;oNJZxUUN3ME25MlQ{QDJzIN88US=>	NGDUPFFUSU6JRWK=
CTV-1	M4nqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXz3XHJRUUN3ME25MlQ{QDl2IN88US=>	M3HIb3NCVkeHUh?=
U-2-OS	NXm5V4s6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[zNmVKSzVyPUmuOFUxODZizszN	MUPTRW5ITVJ?
LB996-RCC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;yVYNwUUN3ME25MlUzOzl5IN88US=>	M4Hj[nNCVkeHUh?=
SK-N-DZ	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jqemlEPTB;OT62OVc1OiEQvF2=	MnvQV2FPT0WU
EFM-19	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTlwN{W1OlYh\|ryP	MYLTRW5ITVJ?
DBTRG-05MG	NGWxe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzjPZRKSzVyPUmuO\|c4PyEQvF2=	MUPTRW5ITVJ?
U-118-MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LEeWlEPTB;OT65OFQ1PCEQvF2=	NX;VSYRMW0GQR1XS
LB1047-RCC	M{OwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnaTWM2OD17Lkm5O\|k5KM7:TR?=	NYHmb3RwW0GQR1XS
NCI-H28	M{WxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHBTWM2OD1zMD60OFE{KM7:TR?=	MV7TRW5ITVJ?
MZ2-MEL	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTFyLkS2O\|ch\|ryP	MmnxV2FPT0WU
M059J	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFyLk[xNFIh\|ryP	NXLVb2xQW0GQR1XS
HT-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHRWHdKSzVyPUGwMlYyPzlizszN	NXjVc4JPW0GQR1XS
SNU-387	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fmU2lEPTB;MUCuO\|I{PSEQvF2=	NF64Wo5USU6JRWK=
NCI-H526	NF21TYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHtTWM2OD1zMT6xN\|Y2KM7:TR?=	M1fUfXNCVkeHUh?=
HEL	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfSR3pKSzVyPUGxMlY2PzlizszN	NIX4W\|BUSU6JRWK=
PA-1	NUTFOGZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPETWM2OD1zMT65N{DPxE1?	Ml61V2FPT0WU
PC-14	NUnycHBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF{LkOyOEDPxE1?	NF7KdoZUSU6JRWK=
C8166	M3:4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVP4Z3c3UUN3ME2xN{4zOzF6IN88US=>	NUfFZlI2W0GQR1XS
NCI-H82	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfyTWM2OD1zMz6yPVA6KM7:TR?=	NY\Hd29[W0GQR1XS
DSH1	NHT4TlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\Bcm1yUUN3ME2xN{4{QDd7IN88US=>	NGnBUpRUSU6JRWK=
T98G	NFHOempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nkT2lEPTB;MUOuOFcyPyEQvF2=	NILheI1USU6JRWK=
KU812	M{Tn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHmwSnZKSzVyPUGzMlUyPzVizszN	MoLaV2FPT0WU
SW48	NHPET3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIC5fVhKSzVyPUGzMlczPjVizszN	NHno[GFUSU6JRWK=
MEL-HO	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTF\|Lki4Nlkh\|ryP	NHH3c49USU6JRWK=
SF539	M{nh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;WVHdMUUN3ME2xOE4xOTF4IN88US=>	M3fFbnNCVkeHUh?=
NB1	NH3ET3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2frfWlEPTB;MUSuNVk{PSEQvF2=	MkfuV2FPT0WU
ST486	NWi5fFNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETDXplKSzVyPUG0MlIzPTFizszN	MkW4V2FPT0WU
LoVo	NXHpXGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnafYtsUUN3ME2xOU4zPjV7IN88US=>	MWLTRW5ITVJ?
NH-12	NYTBSZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DSWWlEPTB;MU[uNFA6PyEQvF2=	M{DBRnNCVkeHUh?=
CCRF-CEM	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrhPGJRUUN3ME2xOk43PzB{IN88US=>	M1HEVnNCVkeHUh?=
Daudi	MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHxT5lKSzVyPUG3MlYyPDlizszN	MWHTRW5ITVJ?
SIMA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTF5LkmxNVgh\|ryP	NIizN2hUSU6JRWK=
8305C	NU\QRolrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTF6LkWzNFUh\|ryP	MmfTV2FPT0WU
EM-2	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkntTWM2OD1zOD62NlQ5KM7:TR?=	NGHDSJlUSU6JRWK=
SNU-449	NULwN5hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTL[pJKSzVyPUG4MlcyPSEQvF2=	MXXTRW5ITVJ?
A101D	M3;pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\QSFhYUUN3ME2xPU4zPDNizszN	NFXVN4VUSU6JRWK=
MHH-NB-11	NHjFeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTF7LkWzOFIh\|ryP	M3n0THNCVkeHUh?=
Becker	NH3iXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXJVGlKSzVyPUKwMlE4PzdizszN	NVvkcGR5W0GQR1XS
NCI-H727	MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\yPGRKSzVyPUKwMlIyPjlizszN	NGXCNYRUSU6JRWK=
HCC1187	NVmzOGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFT6NFhKSzVyPUKwMlM2QDlizszN	M1rpSnNCVkeHUh?=
KYSE-450	NUTXfppPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1K2bmlEPTB;MkGuOVM2PCEQvF2=	M3fIN3NCVkeHUh?=
SK-MEL-28	NGTI[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vuRWlEPTB;MkGuOlg3OyEQvF2=	M4PzRXNCVkeHUh?=
BPH-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfoTWM2OD1{MT63NFM2KM7:TR?=	MYXTRW5ITVJ?
EoL-1-	Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDpTWM2OD1{MT64N\|g2KM7:TR?=	NWLoO4VsW0GQR1XS
TGBC24TKB	NVrNRWVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV6xSmhbUUN3ME2yNU45QTV5IN88US=>	Ml7RV2FPT0WU
KARPAS-299	NYHhWmlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTTTWM2OD1{Mj6xPVU1KM7:TR?=	M1zafHNCVkeHUh?=
SW684	NVm5ZndiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS5T5FsUUN3ME2yNk4zQDV6IN88US=>	NVnqRWpIW0GQR1XS
RXF393	M4PWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrOZplKSzVyPUKyMlYxPjhizszN	MmrXV2FPT0WU
LS-513	NFLCNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr2dXNHUUN3ME2yNk43OTl{IN88US=>	MV;TRW5ITVJ?
KURAMOCHI	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTsWldEUUN3ME2yNk44ODZ7IN88US=>	NY\0fGNHW0GQR1XS
GI-1	NXn3PHk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LFVGlEPTB;MkKuO\|g1OSEQvF2=	M4WxeHNCVkeHUh?=
M14	NWXWNHJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTkTWM2OD1{Mz6xNVMzKM7:TR?=	MXXTRW5ITVJ?
REH	NFfOSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXNPZY4UUN3ME2yN{4yPjl7IN88US=>	NF7KVHBUSU6JRWK=
K5	Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;QN2lEPTB;MkOuOVQ5PiEQvF2=	MVnTRW5ITVJ?
PANC-10-05	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDVfmMyUUN3ME2yOE4xQDl6IN88US=>	M1PzUXNCVkeHUh?=
HMV-II	NHvsUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXiTWM2OD1{ND6yNVY{KM7:TR?=	Mn;XV2FPT0WU
NCI-H1963	Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfx[lRKSzVyPUK0MlI5OzlizszN	MX7TRW5ITVJ?
LU-139	NXnBb5Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzURXlKSzVyPUK0Mlg{PSEQvF2=	NXHkXmdmW0GQR1XS
KASUMI-1	NX;Rb2lWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfGUlFNUUN3ME2yOE46OzJ6IN88US=>	NYHFRmVNW0GQR1XS
RO82-W-1	M3rWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXVTWM2OD1{Nj63N\|c4KM7:TR?=	MkXaV2FPT0WU
NCI-H1770	NVi0d3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33E[GlEPTB;Mk[uPFk5PiEQvF2=	NX3xRmo4W0GQR1XS
SNG-M	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInjVmVKSzVyPUK3MlIzPzFizszN	NX3qT3ZqW0GQR1XS
KLE	M2\0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDWTWM2OD1{Nz6yOVY2KM7:TR?=	MVjTRW5ITVJ?
NCI-H2170	MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\vU\|NKSzVyPUK3MlUzQDJizszN	Ml\ZV2FPT0WU
COLO-792	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4ThcmlEPTB;MkeuO\|czQCEQvF2=	M1LwVXNCVkeHUh?=
ES8	M3fWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LVZ2lEPTB;MkeuO\|gyPCEQvF2=	NXribGNNW0GQR1XS
MC-CAR	MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPMToE5UUN3ME2yO{44QTB5IN88US=>	NH75bmJUSU6JRWK=
SU-DHL-1	NYnBeYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrRS5ZOUUN3ME2yO{46PDd2IN88US=>	M4CyfHNCVkeHUh?=
OAW-28	NWq0W5hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4f1WmlEPTB;MkiuNFA2OiEQvF2=	MYXTRW5ITVJ?
C32	NUHSNGFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DOTGlEPTB;MkiuNFgzPiEQvF2=	NHXIOoFUSU6JRWK=
SW872	M4jPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJ6LkWzNlYh\|ryP	MljDV2FPT0WU
JiyoyeP-2003	NUGySpVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP2TWM2OD1{OT62O\|E6KM7:TR?=	NUTSN49vW0GQR1XS
A204	M2jFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17OemlEPTB;MkmuOlgzQCEQvF2=	MlfzV2FPT0WU
IST-MES1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJ7LkewPVIh\|ryP	NHixUFNUSU6JRWK=
LCLC-103H	M3nZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLUfJlWUUN3ME2zNE4zODV7IN88US=>	M3yxPXNCVkeHUh?=
CAKI-1	M1rMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrXVXhKSzVyPUOwMlI3PTZizszN	NHzBUVZUSU6JRWK=
NALM-6	M1T3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTNyLkS5OlUh\|ryP	M2TSdHNCVkeHUh?=
SK-MM-2	M{fReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPkTWM2OD1\|MD65O\|kzKM7:TR?=	M1POfXNCVkeHUh?=
LB373-MEL-D	NXjLTIo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4f6OmlEPTB;M{GuNFA1PyEQvF2=	MYTTRW5ITVJ?
CAS-1	NV:0fppvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITVfm1KSzVyPUOxMlc3PjVizszN	NGnqeVRUSU6JRWK=
KNS-42	M1TzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfLTWM2OD1\|MT64OlYzKM7:TR?=	NGLKfGVUSU6JRWK=
SW948	M3XZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLUbIJ4UUN3ME2zNk44PTR6IN88US=>	NFG0RlVUSU6JRWK=
HCC1143	NEfvV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LMVGlEPTB;M{KuO\|k4QSEQvF2=	M4HSTnNCVkeHUh?=
NCI-H1648	M4\2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHIflI{UUN3ME2zNk45PDZ5IN88US=>	NWLWOo9oW0GQR1XS
RVH-421	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTN\|LkG2PEDPxE1?	MV7TRW5ITVJ?
KU-19-19	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfwW\|VKSzVyPUOzMlc2OzRizszN	MYDTRW5ITVJ?
PFSK-1	NWXLfWNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTN2LkmyOFEh\|ryP	Mn;CV2FPT0WU
TK10	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fNc2lEPTB;M{WuNVMzOiEQvF2=	NHzs[HZUSU6JRWK=
IGROV-1	M3zINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIL1[mRKSzVyPUO1MlM1OTZizszN	NFHnOpdUSU6JRWK=
EFE-184	NFi3RYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3PdoFGUUN3ME2zOU46OTdizszN	MU\TRW5ITVJ?
8505C	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLvU2RKSzVyPUO1MlkzQTRizszN	NITBXGhUSU6JRWK=
SK-UT-1	M4jCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnlWHZKSzVyPUO2MlM{OzFizszN	M4iyTnNCVkeHUh?=
MKN1	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrj[WNnUUN3ME2zOk45PDR2IN88US=>	M1rn[HNCVkeHUh?=
no-10	NYXBdG9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTN6LkGyPVQh\|ryP	Mki1V2FPT0WU
HT-144	Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTN6LkK1O\|Uh\|ryP	NXLFUIhLW0GQR1XS
CMK	NIjtT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTiTWM2OD1\|OD60NVYzKM7:TR?=	MlLxV2FPT0WU
KM12	NGHEUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTkd3Q6UUN3ME2zPE42QTl6IN88US=>	NIDOOllUSU6JRWK=
HCC2218	NVTmVIdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7SdHpTUUN3ME20NE42QDR7IN88US=>	M4HybHNCVkeHUh?=
BE-13	NUnaOWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTRzLkS0O\|Mh\|ryP	NU\PZW91W0GQR1XS
SK-CO-1	NXfUNGxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfUdIVjUUN3ME20NU44PzV3IN88US=>	M4O1TnNCVkeHUh?=
MPP-89	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{i4bWlEPTB;NEGuPVIyOSEQvF2=	M36xZ3NCVkeHUh?=
NY	MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHS4dpdKSzVyPUSyMlE5ODFizszN	M3XESnNCVkeHUh?=
IST-MEL1	M1v5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTR{Lk[5N\|gh\|ryP	NXnBUW81W0GQR1XS
HCT-116	M4fyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfsTXJqUUN3ME20N{4zODl7IN88US=>	MV;TRW5ITVJ?
LB831-BLC	M{H3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjBdGVKSzVyPUSzMlY6PyEQvF2=	Mn\nV2FPT0WU
TE-8	NV3ubZhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\0TZhyUUN3ME20N{44QDl3IN88US=>	NEPLboRUSU6JRWK=
SR	MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITLPW9KSzVyPUSzMlg3PzNizszN	MlHoV2FPT0WU
ESS-1	NHvuWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTR2LkKwOlIh\|ryP	MYXTRW5ITVJ?
KYSE-270	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTDTWM2OD12NT6wOFM4KM7:TR?=	MXvTRW5ITVJ?
H4	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\xZZJKSzVyPUS1MlMzQTZizszN	NUjsdmZ4W0GQR1XS
COLO-800	M17nbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPFTWM2OD12NT61PFk5KM7:TR?=	Mkj6V2FPT0WU
Ramos-2G6-4C10	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTR4LkC3OVUh\|ryP	NWK1bIpCW0GQR1XS
no-11	M2q5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYriOmk2UUN3ME20Ok4zODNzIN88US=>	NEjCOJhUSU6JRWK=
UACC-62	NFLwc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF36PZZKSzVyPUS2Mlg3ODhizszN	M{LGRXNCVkeHUh?=
D-542MG	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\qTWM2OD12Nz60OVg6KM7:TR?=	MoXlV2FPT0WU
NCI-H747	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTR5LkeyOlQh\|ryP	NFrsVnVUSU6JRWK=
HCC2998	M1zWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\odo5KSzVyPUS4MlI6QDJizszN	M2\nOnNCVkeHUh?=
SNB75	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TSUmlEPTB;NEiuOFEyQCEQvF2=	NInQV2lUSU6JRWK=
COR-L105	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3UTWM2OD12OD65O\|Mh\|ryP	NVTiWZdLW0GQR1XS
SNU-C1	M160VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2KyOGlEPTB;NEmuN\|IxPyEQvF2=	MmHrV2FPT0WU
LC4-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTR7Lki5NVIh\|ryP	Mm[4V2FPT0WU
KS-1	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTVyLkKyNlUh\|ryP	Ml31V2FPT0WU
NCI-H1793	NHe0WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED2bllKSzVyPUWxMlI{OSEQvF2=	NVn5VZhwW0GQR1XS
NCI-H1650	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXzcG1zUUN3ME21NU42QDR7IN88US=>	MmexV2FPT0WU
MCF7	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfLVXhQUUN3ME21NU44PTV2IN88US=>	MlLmV2FPT0WU
SK-N-AS	NFXmO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfYeVFKSzVyPUWxMlgzQDFizszN	MmfwV2FPT0WU
SW837	NXL6XJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGX0ZVNKSzVyPUWxMlk4QDVizszN	Mk\DV2FPT0WU
DB	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\5TWM2OD13MT65PFU2KM7:TR?=	M2D1[nNCVkeHUh?=
CESS	M4HpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\xfmlEPTB;NUKuNVQ2KM7:TR?=	MXrTRW5ITVJ?
CHP-126	NYjzfYY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv2cnpiUUN3ME21N{42OTZ7IN88US=>	NYS0dFV[W0GQR1XS
COLO-824	M1zXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFn3bnhKSzVyPUWzMlY6PzZizszN	NUjQdplCW0GQR1XS
MG-63	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHlVGFKSzVyPUWzMlk{QDFizszN	NGLaZpJUSU6JRWK=
KGN	NGrxbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvGbYNKSzVyPUWzMlk2QSEQvF2=	MkL2V2FPT0WU
697	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1z3NmlEPTB;NUSuNVU2PSEQvF2=	MWnTRW5ITVJ?
MC-IXC	NYXnZmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7QcWNbUUN3ME21OE41OzZ2IN88US=>	M4e1VXNCVkeHUh?=
A375	M3L2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTV2LkiwOVkh\|ryP	NHHZVW1USU6JRWK=
LXF-289	NGDQ[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTV3LkWwOlYh\|ryP	NETsfIhUSU6JRWK=
ES6	NUHLSVhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvYU4F5UUN3ME21OU45QDl7IN88US=>	NGOxUHlUSU6JRWK=
DV-90	NID4R\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTV3Lki5NVch\|ryP	MknvV2FPT0WU
RCM-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHN[FRkUUN3ME21Ok4xODd6IN88US=>	MlnjV2FPT0WU
NCI-H2405	NFLUcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTwTFlKSzVyPUW2MlE3QTNizszN	MXPTRW5ITVJ?
DoTc2-4510	M2SxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXqfo1KSzVyPUW2MlYxPTdizszN	M3GxcXNCVkeHUh?=
RPMI-8866	NHvxfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7OcZdKSzVyPUW3MlI1OTJizszN	MnXOV2FPT0WU
BV-173	MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DS[mlEPTB;NUeuOVE1OiEQvF2=	NWjBXlJPW0GQR1XS
LCLC-97TM1	M2nGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDFb2pKSzVyPUW5MlA2PTNizszN	NH6xXGVUSU6JRWK=
HT-1376	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTV7LkC5NlEh\|ryP	M{S5THNCVkeHUh?=
ACN	NYLqOWFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTV7LkG1PFch\|ryP	MUnTRW5ITVJ?
LU-134-A	NH3DXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDGTWM2OD13OT62NFE3KM7:TR?=	M{P2OXNCVkeHUh?=
SiHa	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nRNGlEPTB;NUmuOlQ5PyEQvF2=	M1WzPXNCVkeHUh?=
EKVX	NXvsbnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDVOIRwUUN3ME22NU41QTV6IN88US=>	Ml3vV2FPT0WU
NMC-G1	M3r4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTTN45KSzVyPU[xMlkzPDJizszN	MkTGV2FPT0WU
NCI-H1734	Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFn2T\|FKSzVyPU[xMlk3PjNizszN	MXTTRW5ITVJ?
K-562	NETGb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Cwd2lEPTB;NkKuNlQ2OiEQvF2=	M{nlTXNCVkeHUh?=
T-24	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy1UlRKSzVyPU[yMlcyOjZizszN	M3fFOHNCVkeHUh?=
SCH	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjISFhyUUN3ME22OE4zOzVzIN88US=>	NXLo[oM5W0GQR1XS
AN3-CA	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LJe2lEPTB;NkSuN\|A{PSEQvF2=	Mk\tV2FPT0WU
MFE-296	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTZ2LkS0O\|Mh\|ryP	MX\TRW5ITVJ?
HuCCT1	M3mxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3FTWM2OD14Nz6wN\|c1KM7:TR?=	NUD3XJRiW0GQR1XS
NCI-H1703	M1vu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjVTWM2OD14OD6xNVcyKM7:TR?=	MlnnV2FPT0WU
C-4-II	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rpS2lEPTB;NkmuN\|YxPyEQvF2=	NHzKO2NUSU6JRWK=
NCI-H2342	MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTZ7LkO5OlEh\|ryP	NEjrV5pUSU6JRWK=
Hs-578-T	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zpWGlEPTB;N{CuN{DPxE1?	NW\Rdo0yW0GQR1XS
HCC1806	MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jpNWlEPTB;N{GuOFU5PyEQvF2=	MlPhV2FPT0WU
EW-16	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3rTWM2OD15MT63OFE2KM7:TR?=	NH3peXBUSU6JRWK=
KALS-1	NW[yUm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjrdmVKSzVyPUezMlU1PzVizszN	MXHTRW5ITVJ?
RT4	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIq0PVNKSzVyPUezMlU4PDJizszN	NHTIe5hUSU6JRWK=
LS-411N	NFPmbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV65e3FCUUN3ME23OE4zPTJ6IN88US=>	NWmyO3V4W0GQR1XS
SK-MEL-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\UZ2lEPTB;N{WuPFAyQSEQvF2=	MmO5V2FPT0WU
8-MG-BA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\VcINqUUN3ME23Ok4yODl4IN88US=>	Mn;VV2FPT0WU
HSC-3	NEHXcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjhVXliUUN3ME23O{4xOjh{IN88US=>	M1vVO3NCVkeHUh?=
NB6	M3TzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTd6LkGyPVkh\|ryP	MlrnV2FPT0WU
PANC-03-27	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHP4RZZKSzVyPUe4MlQ{PSEQvF2=	M3zXOHNCVkeHUh?=
KP-N-YS	NX[4eoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWewUoZ{UUN3ME23PE42QDd6IN88US=>	NXT5c5J3W0GQR1XS
SF295	NWTzUYFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTd7Lkm1OVMh\|ryP	M33BUnNCVkeHUh?=
HCE-T	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnezTWM2OD16MD6xOVg5KM7:TR?=	MmDGV2FPT0WU
KYSE-410	M2HDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDyelhwUUN3ME24NE4zQDV5IN88US=>	M3zVeHNCVkeHUh?=
NB12	MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nTe2lEPTB;OECuPVM3QSEQvF2=	MWTTRW5ITVJ?
NCI-H661	NGLCeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\XTWM2OD16MT6zOFQh\|ryP	Ml3KV2FPT0WU
NCI-H1417	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7y[JNKSzVyPUixMlQ{PjhizszN	M1XYdHNCVkeHUh?=
KMOE-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRThzLki1N\|Eh\|ryP	M2W2bHNCVkeHUh?=
SW1573	M3rad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDaeYVKSzVyPUiyMlU5QTNizszN	M2O3UHNCVkeHUh?=
BFTC-905	M{Hzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfZbGJiUUN3ME24OE4xOTd{IN88US=>	NILPSmhUSU6JRWK=
SBC-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrV[2ZKSzVyPUi0MlAzODhizszN	MXHTRW5ITVJ?
MDA-MB-175-VII	NHS0OJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TVbGlEPTB;OEWuO\|QzPiEQvF2=	Mm\wV2FPT0WU
TE-12	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTh7LkO3OFEh\|ryP	M3rObHNCVkeHUh?=
NCI-H650	NYLXepVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Gy[2lEPTB;OEmuPFczPCEQvF2=	Mn;1V2FPT0WU
C-33-A	NXvtfYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzCdIhKSzVyPUmwMlU1KM7:TR?=	NVW1Tpg3W0GQR1XS
MZ7-mel	M1XDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHNTWM2OD17MT6yOlc3KM7:TR?=	NHvkZY1USU6JRWK=
BOKU	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTl{Lk[5OVch\|ryP	NIDlSFlUSU6JRWK=
CAL-33	NHHuOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi1TWM2OD17Mz6wOlAyKM7:TR?=	MnfBV2FPT0WU
23132-87	NFX0OZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv4TWM2OD17Mz6xOlgh\|ryP	M1fqNnNCVkeHUh?=
J82	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XpfGlEPTB;OUOuO\|gyOSEQvF2=	MYfTRW5ITVJ?
MZ1-PC	NYLJfXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnrTWM2OD17ND61PVg1KM7:TR?=	MXnTRW5ITVJ?
MEL-JUSO	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf6e4dKSzVyPUm0Mlk2PCEQvF2=	M3HYOHNCVkeHUh?=
RMG-I	NFvqN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTl3LkGwO\|Ih\|ryP	NFPFeGNUSU6JRWK=
A2058	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXmybZBpUUN3ME25OU41PjF5IN88US=>	MmDnV2FPT0WU
Caov-4	M1eyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTl3Lk[4OUDPxE1?	MlXsV2FPT0WU
OS-RC-2	NUPpb3FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvXTWM2OD17Nz60OlEh\|ryP	MnTQV2FPT0WU
MKN7	M4HhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTl5Lke0N\|kh\|ryP	MUPTRW5ITVJ?
U-698-M	M2PnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGn2XVRKSzVyPUm4Mlk1QDlizszN	M4nn[HNCVkeHUh?=
PC-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLCbJhYUUN3ME25PU4xPTZ2IN88US=>	MXrTRW5ITVJ?
NCI-H292	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P1WGlEPTB;OUmuN\|AxPCEQvF2=	NWKyU2tyW0GQR1XS
IGR-1	M4q3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTl7LkOxNVkh\|ryP	NUfFfmo3W0GQR1XS
Mewo	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTl7LkW2NFMh\|ryP	NXPpS5BXW0GQR1XS
LU-65	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPUS5NKSzVyPUGwNU4xQDFizszN	Ml:4V2FPT0WU
Saos-2	NXf4d2pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFyMT60N\|ch\|ryP	MWLTRW5ITVJ?
TE-11	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfCXGpKSzVyPUGwNU44OjRizszN	Mnv0V2FPT0WU
SK-MES-1	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHrTWM2OD1zMEGuO\|YzKM7:TR?=	NWfsZXI4W0GQR1XS
KE-37	NV3CVWpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjoeVd3UUN3ME2xNFIvQTVizszN	MVnTRW5ITVJ?
MKN45	MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFyMz61PFQh\|ryP	Mm\oV2FPT0WU
UM-UC-3	NWXS[VhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIi0XlVKSzVyPUGwN{45PDJizszN	NIrFXlVUSU6JRWK=
SNU-C2B	NYLTeGNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHWTWM2OD1zMEWuNFI{KM7:TR?=	MV7TRW5ITVJ?
RPMI-8226	NXqwdodIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInnbIhKSzVyPUGwOk43PzhizszN	NFSw[pZUSU6JRWK=
PANC-08-13	MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrRTWM2OD1zME[uPFUh\|ryP	NHvO[3BUSU6JRWK=
NCI-H23	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFyOD6zOVch\|ryP	NHzOdGFUSU6JRWK=
HOP-92	M4PQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvtd2ZKSzVyPUGwPE41PzVizszN	M{\rU3NCVkeHUh?=
FTC-133	M{D6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrETWM2OD1zMEiuOFg5KM7:TR?=	M{HUdnNCVkeHUh?=
D-263MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojpTWM2OD1zMEiuPVYyKM7:TR?=	MVXTRW5ITVJ?
DU-145	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFyOT65OFUh\|ryP	NGnOUVRUSU6JRWK=
A253	M1yw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HafGlEPTB;MUGwMlQ4QSEQvF2=	NVTtR4VQW0GQR1XS
HCT-15	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTUTGRKSzVyPUGxNE43PjFizszN	NUfzPVJOW0GQR1XS
WSU-NHL	M2SyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFzMj6wNUDPxE1?	M1fse3NCVkeHUh?=
U031	NIXRdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzyOnVKSzVyPUGxNk4xPjVizszN	MULTRW5ITVJ?
MDA-MB-157	NUTrSlJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fDN2lEPTB;MUGyMlQ6KM7:TR?=	NIjlemVUSU6JRWK=
NEC8	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;oTWM2OD1zMUKuOlI1KM7:TR?=	MnnKV2FPT0WU
SIG-M5	M1Pv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX[5VnZUUUN3ME2xNVMvOTJ3IN88US=>	MnjnV2FPT0WU
786-0	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTFzMz60OVMh\|ryP	MlPyV2FPT0WU
DMS-273	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\OOopLUUN3ME2xNVUvPjF5IN88US=>	M3f0[HNCVkeHUh?=
Calu-6	NUP0eph{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDYbpFKSzVyPUGxOk44QThizszN	NXvRU29CW0GQR1XS
HCC1599	NV\HcIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2WwUmlEPTB;MUG3MlE2PiEQvF2=	NIfQPHlUSU6JRWK=
OVCAR-8	M2n2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPyV\|BKSzVyPUGxO{43PjhizszN	NXzTdJU{W0GQR1XS
ATN-1	NGmxclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFzNz64Nlgh\|ryP	MmHPV2FPT0WU
RKO	MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj5[oZKSzVyPUGxO{45QThizszN	NHLab3pUSU6JRWK=
SKG-IIIa	NGCyVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MliwTWM2OD1zMUiuNVE3KM7:TR?=	NHzudVlUSU6JRWK=
SUP-T1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PwbWlEPTB;MUG4Mlk2PiEQvF2=	MlLPV2FPT0WU
KNS-81-FD	M{HTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLre\|dJUUN3ME2xNVkvPDF5IN88US=>	NH3xem9USU6JRWK=
OVCAR-3	NVK2SYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFzOT65NVUh\|ryP	NVTu[I4{W0GQR1XS
NCI-N87	NHjCeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\XTWM2OD1zMkGuNFQ1KM7:TR?=	MmjsV2FPT0WU
HuP-T4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWW1fpNRUUN3ME2xNlEvPTVizszN	MVjTRW5ITVJ?
KYSE-140	NIrRboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnyZZVWUUN3ME2xNlIvOTRzIN88US=>	MlLqV2FPT0WU
HAL-01	NYPr[Yl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPaPZFKSzVyPUGyNk41QTlizszN	NXn0[JN1W0GQR1XS
HT-29	M4LoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\2TGlEPTB;MUKyMlc4QCEQvF2=	MmrWV2FPT0WU
OPM-2	M3nGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPqTVFWUUN3ME2xNlMvOTd4IN88US=>	NFz2UolUSU6JRWK=
SW1463	M1P5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7rTWM2OD1zMkSuNFc4KM7:TR?=	NYTOXm11W0GQR1XS
NCI-H2087	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPGSJZKSzVyPUGyOE4zQDNizszN	MknDV2FPT0WU
UMC-11	NH7qZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzITWM2OD1zMk[uNFM5KM7:TR?=	MWHTRW5ITVJ?
EB-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjZOINqUUN3ME2xNlcvODF\|IN88US=>	M2DKWnNCVkeHUh?=
HEC-1	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTF{OT6xPVgh\|ryP	NH;pNZhUSU6JRWK=
LU-99A	M2LofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TwPGlEPTB;MUK5Mlk{OSEQvF2=	NF;NdXJUSU6JRWK=
VMRC-RCZ	NHjY[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF\|MD6zO\|Uh\|ryP	NEnh[2VUSU6JRWK=
MFH-ino	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDqeXZnUUN3ME2xN\|EvOTF2IN88US=>	MmLWV2FPT0WU
HT-1080	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[2dWlEPTB;MUOyMlIxPCEQvF2=	M1;KT3NCVkeHUh?=
CTB-1	NWS2XFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;aV\|ZKSzVyPUGzNk45QTdizszN	Mn75V2FPT0WU
Capan-2	M4C3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkn4TWM2OD1zM{OuPVc2KM7:TR?=	MnvIV2FPT0WU
BB30-HNC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTF\|ND6xNVYh\|ryP	NYO0VFgyW0GQR1XS
CP50-MEL-B	M{\PXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPab5NKSzVyPUGzOE4zKM7:TR?=	NV;WZmY2W0GQR1XS
JEG-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jXWmlEPTB;MUO0MlM2QSEQvF2=	NVfpUndnW0GQR1XS
NCI-H1437	M{HYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTF\|ND61PUDPxE1?	MoGyV2FPT0WU
NOS-1	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzkWXBqUUN3ME2xN\|QvPzZ3IN88US=>	M4Th[HNCVkeHUh?=
G-402	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrTTWM2OD1zM{WuNlk2KM7:TR?=	NYDmXYpQW0GQR1XS
OAW-42	NF;TTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jFSmlEPTB;MUO3Mlg2PiEQvF2=	M1XGWXNCVkeHUh?=
Ca-Ski	M2rWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXuUpk4UUN3ME2xN\|gvQDNzIN88US=>	MlTqV2FPT0WU
BHT-101	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjqW4xKSzVyPUG0NE4zODhizszN	M2LZOXNCVkeHUh?=
OVCAR-4	M4rMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF2MD63OFkh\|ryP	NEm1[\|JUSU6JRWK=
Detroit562	NFPkU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\hTWM2OD1zNEGuOFY3KM7:TR?=	NIPJN29USU6JRWK=
OCI-AML2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzqWnNGUUN3ME2xOFEvPTB5IN88US=>	MVPTRW5ITVJ?
OE33	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT4fIRKSzVyPUG0NU44QThizszN	NUfp[ZE5W0GQR1XS
YKG-1	Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\KVppWUUN3ME2xOFIvQDh7IN88US=>	M3H5dHNCVkeHUh?=
CCF-STTG1	NX\5SJg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTF2Mz6zN\|Qh\|ryP	MknqV2FPT0WU
NCI-H810	NG\GTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvwRnFKSzVyPUG0N{43QDdizszN	NXjSNVlDW0GQR1XS
SCC-25	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfWR45KSzVyPUG0OE4xODVizszN	NHLNR3NUSU6JRWK=
HTC-C3	NHHyW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnRblVkUUN3ME2xOFUvODd3IN88US=>	MojlV2FPT0WU
G-401	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXKTWM2OD1zNEWuPFM2KM7:TR?=	M1TYNnNCVkeHUh?=
OMC-1	NIHjTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXKwUVdwUUN3ME2xOFUvQTZ5IN88US=>	NW[zU2lxW0GQR1XS
LK-2	M{j3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvhOlJKSzVyPUG0O{4yPDNizszN	MoS0V2FPT0WU
SW13	NX6wRmozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rBUGlEPTB;MUS3MlI2OyEQvF2=	MoTWV2FPT0WU
BB49-HNC	M2H5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHITWM2OD1zNEeuOFA1KM7:TR?=	M4j0[3NCVkeHUh?=
DMS-114	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HoeGlEPTB;MUS3MlQ1OSEQvF2=	NVLjWHJQW0GQR1XS
GCIY	MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\BWY1{UUN3ME2xOFcvPzl5IN88US=>	NIraTYdUSU6JRWK=
GAMG	NYXReHpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV74VoZZUUN3ME2xOFgvOjR5IN88US=>	NVnJWphwW0GQR1XS
KYSE-520	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHvTWM2OD1zNEiuOVQh\|ryP	M2PkZXNCVkeHUh?=
LB647-SCLC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjOTWM2OD1zNEiuOVYzKM7:TR?=	NIjF[I1USU6JRWK=
639-V	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LaTWlEPTB;MUS4MlcxPSEQvF2=	NEDNcYxUSU6JRWK=
TE-9	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2e4[GlEPTB;MUS5MlQ1OyEQvF2=	MnjBV2FPT0WU
Caov-3	M1HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTF2OT63NVQh\|ryP	MXfTRW5ITVJ?
L-540	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1joOmlEPTB;MUS5Mlc2KM7:TR?=	NFfKPIRUSU6JRWK=
NCI-H748	NI\ncpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2O2O2lEPTB;MUWwMlIxQSEQvF2=	NYLoSHFPW0GQR1XS
GDM-1	MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTF3MT6xN\|Uh\|ryP	NXzseJRPW0GQR1XS
GAK	NH;QWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\4PFNKSzVyPUG1NU4{PzRizszN	NYL4OJZPW0GQR1XS
AsPC-1	NFf4fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnKcJN3UUN3ME2xOVIvPzZ2IN88US=>	MV7TRW5ITVJ?
MDA-MB-361	NYC4e5FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTF3Mz6xOlQh\|ryP	NYe3cVVZW0GQR1XS
TT	M{G0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzsTWM2OD1zNUOuOFkh\|ryP	M3jmRnNCVkeHUh?=
Calu-1	NYfvU4llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHVZVg6UUN3ME2xOVQvODB\|IN88US=>	MXLTRW5ITVJ?
RERF-LC-MS	M4fHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTF3ND63O\|Ih\|ryP	NGnDV4VUSU6JRWK=
DK-MG	NWHDbndjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHq1RXRKSzVyPUG1OU4yQDNizszN	M2PhV3NCVkeHUh?=
CAL-120	NXTqVWZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXPOnkxUUN3ME2xOVUvQDJzIN88US=>	NWn1TpVTW0GQR1XS
HCC1419	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmCxTWM2OD1zNU[uNFc4KM7:TR?=	NUHBS294W0GQR1XS
DG-75	NEjCbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnm2TWM2OD1zNU[uOlk1KM7:TR?=	Mkj1V2FPT0WU
HCC38	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\NTWM2OD1zNUeuN\|Y6KM7:TR?=	M{PLeHNCVkeHUh?=
HCC70	M{\vcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PDSWlEPTB;MUW5MlI1OiEQvF2=	MmPMV2FPT0WU
ES4	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkW0TWM2OD1zNUmuN\|k3KM7:TR?=	MUfTRW5ITVJ?
NCI-H2052	NEi3dYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTNTWM2OD1zNUmuOVg{KM7:TR?=	NF6y[IJUSU6JRWK=
EFO-27	NX63dWJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nFemlEPTB;MU[wMlU5PCEQvF2=	MWLTRW5ITVJ?
CAL-62	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLKW3BVUUN3ME2xOlIvPjF\|IN88US=>	NHT6clZUSU6JRWK=
CHP-212	NGnrd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;ZbGlEPTB;MU[zMlYzPiEQvF2=	NVnuPIt3W0GQR1XS
AU565	M1Sycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVS5PHZmUUN3ME2xOlMvPjRizszN	NWTVV3JyW0GQR1XS
Ca9-22	M2Hvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF4ND6zNlEh\|ryP	M1XHVnNCVkeHUh?=
EFO-21	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\mTGlEPTB;MU[1MlQ2KM7:TR?=	M{PmSnNCVkeHUh?=
KINGS-1	M3zKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTF4Nz6zOVQh\|ryP	MkG2V2FPT0WU
JVM-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NISxbppKSzVyPUG2O{41PTFizszN	M2S1bXNCVkeHUh?=
OVCAR-5	M4S5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjnTWM2OD1zNkiuN\|A6KM7:TR?=	MVnTRW5ITVJ?
Calu-3	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHRXGVpUUN3ME2xOlgvOzFzIN88US=>	M2XhNXNCVkeHUh?=
CP66-MEL	NUTDTZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnkTWM2OD1zNkiuOFE2KM7:TR?=	MU\TRW5ITVJ?
KYSE-150	NGHpWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPuTWM2OD1zNkmuOlM3KM7:TR?=	MVfTRW5ITVJ?
Daoy	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\zTJVKSzVyPUG2PU45QTFizszN	M4LVb3NCVkeHUh?=
HUTU-80	NY\n[GhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4KyV2lEPTB;MUexMlA{OiEQvF2=	NWrrNnViW0GQR1XS
SW620	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rnXWlEPTB;MUexMlU{PSEQvF2=	MnToV2FPT0WU
HuO-3N1	NGDyPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF5Mj6yO\|Mh\|ryP	NXrBTWNuW0GQR1XS
HH	MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTF5Mz64OFgh\|ryP	NXuyPY1MW0GQR1XS
ME-180	NGW4VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\2[2w1UUN3ME2xO\|QvODF4IN88US=>	NYrPc3N6W0GQR1XS
SW756	M1i0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTF5ND64OlMh\|ryP	NYnKdpI1W0GQR1XS
LNCaP-Clone-FGC	NW\nNo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7qTWM2OD1zN{WuPFYyKM7:TR?=	M2fifHNCVkeHUh?=
YT	M2\qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoL0TWM2OD1zN{[uN\|k6KM7:TR?=	NUPKOJBiW0GQR1XS
EW-3	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1K1e2lEPTB;MUe2MlU2PSEQvF2=	MlrjV2FPT0WU
COLO-741	M37oVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHtOXFsUUN3ME2xO\|cvPTZzIN88US=>	NHn0OnlUSU6JRWK=
SK-NEP-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknBTWM2OD1zN{euPFA3KM7:TR?=	MoPNV2FPT0WU
NB10	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\sVHY3UUN3ME2xO\|cvQDR4IN88US=>	NV;Ye2RkW0GQR1XS
SF126	M1vkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjRe3BKSzVyPUG3PU41OzJizszN	MU\TRW5ITVJ?
NCI-H522	NVnpNZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF6MT6wOVkh\|ryP	NF3ndWNUSU6JRWK=
PSN1	NH7VZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnPcpBkUUN3ME2xPFEvPjZizszN	M1HFNnNCVkeHUh?=
GI-ME-N	NXTWO5NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFG1SmxKSzVyPUG4NU43PzJizszN	NYXGO49NW0GQR1XS
SBC-5	NIXkU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[1Z2lEPTB;MUixMlk{PCEQvF2=	NYCwT4prW0GQR1XS
ONS-76	NFTzTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{O1WmlEPTB;MUiyMlM5PyEQvF2=	MWrTRW5ITVJ?
LOUCY	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTF6Mj62PFgh\|ryP	MVXTRW5ITVJ?
SN12C	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTp[GNKSzVyPUG4Nk45OjlizszN	M3zxRXNCVkeHUh?=
A427	MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPmcZVNUUN3ME2xPFQvPjNzIN88US=>	NWrh[XpXW0GQR1XS
DOK	NHfKeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfkfppKSzVyPUG4OE43PDNizszN	MnXyV2FPT0WU
MDA-MB-415	MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPB[nhKSzVyPUG4OE43PTFizszN	NYTi[GxbW0GQR1XS
MRK-nu-1	NIDqVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTF6ND65O\|Ih\|ryP	MnjyV2FPT0WU
LB2241-RCC	NWrwc2tIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HhVWlEPTB;MUi1MlE1PSEQvF2=	MYnTRW5ITVJ?
NCI-H1563	NFjMSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkH6TWM2OD1zOEWuNlA6KM7:TR?=	NIfscpJUSU6JRWK=
MDA-MB-453	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF6Nj65OFEh\|ryP	M3rHUXNCVkeHUh?=
MONO-MAC-6	NYPXcGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTF6Nz6zPVIh\|ryP	NIXXepBUSU6JRWK=
CAPAN-1	NVTDcmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXpcoNKSzVyPUG4O{41PTNizszN	NV7xZo41W0GQR1XS
SK-LU-1	M3e0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVG3[WRoUUN3ME2xPFgvPDJ6IN88US=>	M3vO[nNCVkeHUh?=
NCI-H1299	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjUUGFKSzVyPUG4PE44OTlizszN	MV3TRW5ITVJ?
KG-1	NFfvcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFS1clhKSzVyPUG4PU44QThizszN	M4P1N3NCVkeHUh?=
ETK-1	M{jIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XhRWlEPTB;MUmwMlE5OSEQvF2=	MkfUV2FPT0WU
NCI-H838	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnFTWM2OD1zOUCuN\|Qh\|ryP	MknCV2FPT0WU
HCE-4	NFjjVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nWTWlEPTB;MUmwMlk6OiEQvF2=	MnvpV2FPT0WU
A2780	NEDUVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHKyWnFKSzVyPUG5Nk45QTFizszN	MoDTV2FPT0WU
COLO-668	NXzpd5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XF[2lEPTB;MUmzMlE2PyEQvF2=	NVPyd446W0GQR1XS
HGC-27	MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTF7NT61N\|gh\|ryP	M{XscXNCVkeHUh?=
SW1088	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTYTWM2OD1zOUWuOlc4KM7:TR?=	Mn3EV2FPT0WU
KOSC-2	M{XHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvC[3VKSzVyPUG5OU45OThizszN	M1TJUHNCVkeHUh?=
TE-1	M2HEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzPRZNKSzVyPUG5Ok4zPiEQvF2=	NF\YWodUSU6JRWK=
SW780	M{DhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\zS4xKSzVyPUG5Ok44OzRizszN	NXnhXHU6W0GQR1XS
22RV1	NHPZWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH1RnVKSzVyPUG5O{41OjRizszN	M1nuSXNCVkeHUh?=
IA-LM	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTF7Nz64NlIh\|ryP	MYXTRW5ITVJ?
TE-5	NILNeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfl[4lKSzVyPUG5PE4xOzNizszN	NHrKdXVUSU6JRWK=
JVM-3	NIHRUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLQZnlDUUN3ME2xPVgvPDF7IN88US=>	NUnLenZ6W0GQR1XS
HT55	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTF7OT6xPVIh\|ryP	Mn3lV2FPT0WU
QIMR-WIL	MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJyMD6xNVYh\|ryP	NGnPPW9USU6JRWK=
SJRH30	NEj0NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4j1dWlEPTB;MkCwMlUyPSEQvF2=	MmK2V2FPT0WU
COLO-679	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInmd3dKSzVyPUKwNE45PTlizszN	NYfkNHJ6W0GQR1XS
MDA-MB-231	NFS1SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnxTWM2OD1{MECuPVAzKM7:TR?=	M{TmbnNCVkeHUh?=
MFM-223	NE[xfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\DfWlEPTB;MkCxMlU5PyEQvF2=	MVrTRW5ITVJ?
MFE-280	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnn0TWM2OD1{MEGuPVYyKM7:TR?=	NIDpWHVUSU6JRWK=
LAMA-84	NX7INVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF2wVm1KSzVyPUKwNk4xPzNizszN	NUe2ZXhFW0GQR1XS
LS-1034	NX62ZZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\OdnU1UUN3ME2yNFIvPTV\|IN88US=>	NVW0OVlbW0GQR1XS
NCI-H345	MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVH3eYFYUUN3ME2yNFMvODJ5IN88US=>	M4GzdHNCVkeHUh?=
KYSE-70	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTJyMz64O\|kh\|ryP	NH;EbndUSU6JRWK=
EGI-1	M2jhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTJyND64N\|Mh\|ryP	MkjkV2FPT0WU
RPMI-2650	NV;ZZlFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTJyNT60Olch\|ryP	NVi1V3BkW0GQR1XS
NCI-H1651	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTUdWR[UUN3ME2yNFYvPzNizszN	NEKz[4JUSU6JRWK=
HPAF-II	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoH6TWM2OD1{MEmuOlcyKM7:TR?=	Mm\JV2FPT0WU
NUGC-3	NFS3cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGroTGNKSzVyPUKwPU43PzhizszN	M3i4fnNCVkeHUh?=
DJM-1	NIj5N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJyOT64PVch\|ryP	MkW3V2FPT0WU
MHH-PREB-1	NHnzclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTJzMD6zPFEh\|ryP	MoLIV2FPT0WU
EW-18	NWTk[phZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7nTWM2OD1{MUCuO\|Y{KM7:TR?=	MmDwV2FPT0WU
BT-20	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTJzMD65PFYh\|ryP	NE\3[GxUSU6JRWK=
A431	MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rRU2lEPTB;MkGxMlI6QSEQvF2=	NH3UOJFUSU6JRWK=
TCCSUP	NHi5V3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrDeW1KSzVyPUKxNU42OzNizszN	M2[yW3NCVkeHUh?=
HO-1-N-1	NGPRfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLSTWM2OD1{MUKuPFk1KM7:TR?=	M4TJWXNCVkeHUh?=
NCI-H69	M4q0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rCPGlEPTB;MkG0MlE5PSEQvF2=	M4LTb3NCVkeHUh?=
ES7	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\kbnRKSzVyPUKxOE45PzhizszN	MkXFV2FPT0WU
C3A	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjUTWM2OD1{MUWuOVc2KM7:TR?=	NV\wVFdyW0GQR1XS
UACC-257	NUXPNo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1X0T2lEPTB;MkG3MlQ{KM7:TR?=	NWDlc4kzW0GQR1XS
DMS-153	NUfzOm1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHW[nR4UUN3ME2yNVcvQDN4IN88US=>	MXzTRW5ITVJ?
LB771-HNC	NXLEeoxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInaVHJKSzVyPUKxO{45QTNizszN	NXPUeYVLW0GQR1XS
HOS	M4XXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXjTWM2OD1{MUiuPUDPxE1?	Mn;WV2FPT0WU
THP-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\1WWlEPTB;MkG5MlYxPiEQvF2=	MYHTRW5ITVJ?
SCC-4	NWjOXZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HUSmlEPTB;MkKwMlM2OyEQvF2=	NYG5UIxZW0GQR1XS
SCC-3	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDtTWM2OD1{MkCuOVc4KM7:TR?=	NGS0UYRUSU6JRWK=
BC-1	NX3YcmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWezRmxmUUN3ME2yNlAvPzl7IN88US=>	M2jpfHNCVkeHUh?=
NCI-H1618	NF7JRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfhcoZKSzVyPUKyNU4xOThizszN	NEXrfnFUSU6JRWK=
CaR-1	NFHrdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLGTWM2OD1{MkGuNlUyKM7:TR?=	MonvV2FPT0WU
NCI-H1355	M2e1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrs[WFKSzVyPUKyNU4{PzdizszN	NVXEV2d4W0GQR1XS
NCI-H1993	MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTJ{Mj6yN\|kh\|ryP	MX\TRW5ITVJ?
NCI-H1623	M3HsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGC3eVNKSzVyPUKyNk4{QDlizszN	MVHTRW5ITVJ?
AGS	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rye2lEPTB;MkKyMlUzOyEQvF2=	MUjTRW5ITVJ?
SAS	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTCeo5KSzVyPUKyN{44QTZizszN	M1PmWnNCVkeHUh?=
HCC1937	NGXRXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fkZmlEPTB;MkK0MlM5QSEQvF2=	M1S1ZnNCVkeHUh?=
NCI-H209	M{j4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTJ{Nj61N{DPxE1?	MYjTRW5ITVJ?
NCI-H322M	MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTJ{OD6wNVkh\|ryP	NGjsTVVUSU6JRWK=
CHL-1	NW\CcoRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTUTWM2OD1{MkiuNVMh\|ryP	MmT0V2FPT0WU
NCI-H630	NWjifllMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[yXGJKSzVyPUKzNk45QTdizszN	M3PqRnNCVkeHUh?=
5637	NEfaWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfMdolKSzVyPUKzN{4xODNizszN	MoT5V2FPT0WU
MSTO-211H	M2rCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXqTWM2OD1{M{OuNlc3KM7:TR?=	MkDjV2FPT0WU
YAPC	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXCbItKSzVyPUKzOE4zPTNizszN	MkHLV2FPT0WU
SW1783	NHnscZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\HPGlEPTB;MkO0MlQyKM7:TR?=	NXv2R\|B2W0GQR1XS
GB-1	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HmbmlEPTB;MkO1MlE4PyEQvF2=	M2LmXHNCVkeHUh?=
NCI-H520	NIXYWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\xe2dSUUN3ME2yN\|UvPzRzIN88US=>	M3nDVnNCVkeHUh?=
NOMO-1	M324eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXq0Z2RSUUN3ME2yN\|YvODJizszN	MnjRV2FPT0WU
NCCIT	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVviOHBHUUN3ME2yN\|YvQDd\|IN88US=>	NFzpZ2pUSU6JRWK=
SW954	NYDRUYFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmX0TWM2OD1{M{euPFY5KM7:TR?=	MVTTRW5ITVJ?
MOLT-4	M13ZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfqTWM2OD1{NEGuNlA6KM7:TR?=	NH3NboRUSU6JRWK=
EB2	M4LBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonrTWM2OD1{NEGuPVA4KM7:TR?=	M1y0OHNCVkeHUh?=
IPC-298	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHhTWM2OD1{NEKuNFczKM7:TR?=	NVXYT5JVW0GQR1XS
GP5d	M3LtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;XdWlEPTB;MkSyMlYyPiEQvF2=	NH;0NIJUSU6JRWK=
HN	M2rOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;jT2lEPTB;MkSyMlk6OSEQvF2=	NWW1[XNTW0GQR1XS
BFTC-909	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nkd2lEPTB;MkSzMlEyQCEQvF2=	M163RXNCVkeHUh?=
ES5	NHTGZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLs[XFQUUN3ME2yOFUvODN6IN88US=>	M1TsfHNCVkeHUh?=
SK-HEP-1	NXTPT5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{L0XGlEPTB;MkS2MlA1OyEQvF2=	MUXTRW5ITVJ?
T47D	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T5[mlEPTB;MkS3MlAyOyEQvF2=	NV74PVliW0GQR1XS
KYSE-510	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL5TWM2OD1{NEeuOVE4KM7:TR?=	MVHTRW5ITVJ?
LC-1F	M2fDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPQVZpKSzVyPUK0PE4yPTZizszN	NWDIOGZbW0GQR1XS
NCI-H1693	M4fBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJ2OT60PVUh\|ryP	MlLlV2FPT0WU
COR-L23	M1vxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTJ3MD60NVIh\|ryP	MnzCV2FPT0WU
NCI-H2228	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoOwTWM2OD1{NUCuPFY1KM7:TR?=	M3HMNnNCVkeHUh?=
NCI-H460	NF\4TlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu0UpBKSzVyPUK1NU41OTdizszN	NXOxOWM5W0GQR1XS
TGBC1TKB	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrYe5IxUUN3ME2yOVIvQDd3IN88US=>	MYHTRW5ITVJ?
NCI-H1304	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fSVGlEPTB;MkWzMlE2PiEQvF2=	MXnTRW5ITVJ?
CAL-27	M4nGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HoZWlEPTB;MkWzMlQ5PSEQvF2=	NITS[VBUSU6JRWK=
NCI-H187	NXHlVldvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJ3Nj63OkDPxE1?	NGHu[JlUSU6JRWK=
HSC-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDsb5RKSzVyPUK1PE42QDRizszN	MnP1V2FPT0WU
CAL-39	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTTTJM4UUN3ME2yOlAvOjd{IN88US=>	NXW3S4I5W0GQR1XS
HuH-7	M2jyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXGV29KSzVyPUK2NE46QTZizszN	NWjEbJV7W0GQR1XS
MMAC-SF	Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjpblFbUUN3ME2yOlEvOTl{IN88US=>	MV;TRW5ITVJ?
VA-ES-BJ	M3LPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn:1TWM2OD1{NkGuPVE5KM7:TR?=	NHLk[\|VUSU6JRWK=
A673	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjuTWM2OD1{NkeuNFI2KM7:TR?=	NHq2NmlUSU6JRWK=
LU-165	MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DxWWlEPTB;Mk[3Mlk1OSEQvF2=	Mm\KV2FPT0WU
CAL-12T	M1vLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7YTWM2OD1{NkiuN\|Y3KM7:TR?=	MV3TRW5ITVJ?
RD	M3OxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIKzS\|lKSzVyPUK2PU4yOTlizszN	NV;YVWFIW0GQR1XS
MDA-MB-468	NGHldItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vTS2lEPTB;Mk[5MlM{OyEQvF2=	NWiwXYd1W0GQR1XS
LN-405	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\zTWM2OD1{NkmuO\|A5KM7:TR?=	MWDTRW5ITVJ?
MHH-CALL-2	M37Wc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnO4TWM2OD1{NkmuPVIh\|ryP	Mk\XV2FPT0WU
ES3	M2nCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;PZZhKSzVyPUK3NE4{PThizszN	NYniUIZRW0GQR1XS
SK-MEL-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnRb\|JKSzVyPUK3OU41PTdizszN	NFXJSndUSU6JRWK=
TE-10	M4HQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEm4V2xKSzVyPUK3Ok41OzlizszN	NYrsO\|hJW0GQR1XS
BEN	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJ5Nj60OlEh\|ryP	Mm\nV2FPT0WU
NB69	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjBOWZKSzVyPUK3O{41ODVizszN	NV3zXlRpW0GQR1XS
CAMA-1	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPnXlRzUUN3ME2yO\|gvOjd7IN88US=>	M{PZbnNCVkeHUh?=
NCI-H1792	NUjtU45WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\6UlRFUUN3ME2yO\|kvOTh5IN88US=>	NVzQNZFzW0GQR1XS
UACC-893	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nEVmlEPTB;MkiwMlU1KM7:TR?=	MkTaV2FPT0WU
TGW	NEnLdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDmcoxUUUN3ME2yPFMvODV6IN88US=>	M1XjNnNCVkeHUh?=
SH-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLIU\|VEUUN3ME2yPFMvOTJ\|IN88US=>	NI\5flFUSU6JRWK=
NCI-H2009	NGrMcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTJ6Mz65OVMh\|ryP	NVXUfmFJW0GQR1XS
T84	NWXBe5hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELNR2ZKSzVyPUK4OE43PjVizszN	NXHK[Fc{W0GQR1XS
EW-7	NUnQ[mpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofKTWM2OD1{OEWuNlMzKM7:TR?=	M2fmenNCVkeHUh?=
NCI-H1882	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HRb2lEPTB;Mki2MlA{PSEQvF2=	MkDqV2FPT0WU
GMS-10	NY\Pd5FPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLETWM2OD1{OEeuNVg{KM7:TR?=	NEW0[IxUSU6JRWK=
HC-1	NELWWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjL[pduUUN3ME2yPVAvPjB{IN88US=>	MVLTRW5ITVJ?
ABC-1	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LJOmlEPTB;MkmxMlA3QSEQvF2=	M3zlWnNCVkeHUh?=
HuP-T3	NHPuNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkf2TWM2OD1{OUKuNVQ3KM7:TR?=	MlfFV2FPT0WU
HT-1197	M1jXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTJ7Mj64O\|kh\|ryP	NFe1UY9USU6JRWK=
SHP-77	NIjFU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\U[VI6UUN3ME2yPVUvPTl5IN88US=>	NVn4bYFmW0GQR1XS
NCI-H524	MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmqyTWM2OD1{OUWuO\|Y6KM7:TR?=	MkfXV2FPT0WU
SW626	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;Vb3NKSzVyPUK5Ok4yOTVizszN	MWLTRW5ITVJ?
NCI-H2347	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJ7Nj60NlUh\|ryP	NXjsb4k6W0GQR1XS
U251	NFv3W2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHP0Z4ZKSzVyPUK5PE41OzhizszN	NF;XRm5USU6JRWK=
RL95-2	NXjH[3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TzTGlEPTB;M{CwMlI1PyEQvF2=	NYDHcIFyW0GQR1XS
C2BBe1	NHPkdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrrW\|hKSzVyPUOwNE43QTFizszN	NILoboNUSU6JRWK=
HLE	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nrVGlEPTB;M{CxMlgyQCEQvF2=	MkK0V2FPT0WU
COLO-680N	MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml:1TWM2OD1\|MEKuPFk{KM7:TR?=	Mo\GV2FPT0WU
PLC-PRF-5	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnyd3ZKSzVyPUOwOE46ODdizszN	M33KNnNCVkeHUh?=
SCC-15	NUHIeYVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTNyNj6wNVch\|ryP	NV;2bWF[W0GQR1XS
ECC12	NULHZ5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDFVpFKSzVyPUOxNE4zPTRizszN	NIPvOW5USU6JRWK=
A388	M3jxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnKxTWM2OD1\|MUKuNFIzKM7:TR?=	NIfDdnlUSU6JRWK=
ES1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTNzMj6xPFkh\|ryP	MojTV2FPT0WU
J-RT3-T3-5	NVH2NpBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfuZnJKSzVyPUOxN{42OjFizszN	NYLleWRIW0GQR1XS
SNU-475	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2roeWlEPTB;M{G0MlA6OSEQvF2=	NEW3VWhUSU6JRWK=
647-V	NV\5THVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTNzND62O\|Mh\|ryP	MUTTRW5ITVJ?
IMR-5	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLN[oZyUUN3ME2zNVUvOzhizszN	NV\UR4ExW0GQR1XS
EW-24	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDJOZdMUUN3ME2zNlAvODdizszN	NWHWToRWW0GQR1XS
CAL-51	NFH1SpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTN{MT60NFMh\|ryP	NXfGVFBiW0GQR1XS
HD-MY-Z	NWDPcnIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NICyRWhKSzVyPUOyNU41ODlizszN	MUTTRW5ITVJ?
EW-13	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjB[lU4UUN3ME2zNlIvPDJ2IN88US=>	NWDW[4Y1W0GQR1XS
SK-N-FI	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnH3TWM2OD1\|MkKuOFUzKM7:TR?=	M2HvNnNCVkeHUh?=
BHY	NH;UbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO1Xm5jUUN3ME2zNlMvOTd3IN88US=>	NWjId3lOW0GQR1XS
OCUB-M	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXv1TpB{UUN3ME2zNlMvPDN2IN88US=>	MoT6V2FPT0WU
HCC1954	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoT3TWM2OD1\|MkOuOVgzKM7:TR?=	NEHMT\|dUSU6JRWK=
SK-MEL-24	NFH5cpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTN{ND6xNVEh\|ryP	M3TC[XNCVkeHUh?=
NTERA-S-cl-D1	NX[4WWliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTN{Nj60PFkh\|ryP	MXPTRW5ITVJ?
SK-MEL-30	NYDPWJJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13McmlEPTB;M{K2Mlc{QCEQvF2=	NUDVfoRmW0GQR1XS
LS-123	NXzRc2xZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTPTY9WUUN3ME2zNlgvOTZ2IN88US=>	M{GyS3NCVkeHUh?=
SF268	NYrSeWJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETkU2RKSzVyPUOzNE4zPjVizszN	MoDWV2FPT0WU
BT-474	M4jHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfYVmZuUUN3ME2zN\|IvPDF6IN88US=>	NH;JO\|ZUSU6JRWK=
NCI-H1522	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXSboJKSzVyPUOzOE4{OzlizszN	M2fydnNCVkeHUh?=
LC-2-ad	NYHxSG41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fkNWlEPTB;M{O2MlU6OSEQvF2=	MmHGV2FPT0WU
LAN-6	NF\MN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4q2O2lEPTB;M{O2Mlk4PyEQvF2=	MYHTRW5ITVJ?
ARH-77	NH7kenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nRUWlEPTB;M{O3MlMzKM7:TR?=	NUjKZW54W0GQR1XS
HuO9	NWfk[GExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jIOWlEPTB;M{O3MlQ4KM7:TR?=	MlPwV2FPT0WU
MLMA	M{jnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPveVdKSzVyPUOzPE4yPTVizszN	MXLTRW5ITVJ?
Raji	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3qxWmlEPTB;M{O4MlM5KM7:TR?=	MVTTRW5ITVJ?
GT3TKB	NGLJclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\qZpZFUUN3ME2zN\|gvPDF{IN88US=>	MW\TRW5ITVJ?
NCI-H441	NVP5XZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN2MT60NVgh\|ryP	MXrTRW5ITVJ?
NCI-H2030	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljhTWM2OD1\|NEGuOlA6KM7:TR?=	MVnTRW5ITVJ?
VM-CUB-1	M2S2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITvb5lKSzVyPUO0Nk43OzZizszN	NIjSO49USU6JRWK=
KP-4	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;zZ5NMUUN3ME2zOFMvPzN\|IN88US=>	MofIV2FPT0WU
PF-382	MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTN2ND60NlIh\|ryP	NVLXb2hDW0GQR1XS
NB13	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDkXnA2UUN3ME2zOFUvPThizszN	NV\TdZNYW0GQR1XS
D-502MG	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vrfGlEPTB;M{S1MlgyOiEQvF2=	NVW0[YV3W0GQR1XS
CAL-54	NUPieVJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HtcmlEPTB;M{S1Mlg4QSEQvF2=	M17pNHNCVkeHUh?=
DOHH-2	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIq2XWRKSzVyPUO0Ok43PSEQvF2=	Mnv0V2FPT0WU
SK-PN-DW	MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnu2TWM2OD1\|NEeuOFI3KM7:TR?=	NHHRfHhUSU6JRWK=
NCI-H720	M4TmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTN2OT64OFYh\|ryP	M3\2ZXNCVkeHUh?=
SW1990	M{HxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDGV4tRUUN3ME2zOVEvOjhizszN	M2KzWnNCVkeHUh?=
NCI-H2196	NEnTXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LMe2lEPTB;M{WyMlYzPCEQvF2=	NI\5Uo1USU6JRWK=
P30-OHK	M4\uZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XSPGlEPTB;M{WzMlA3OyEQvF2=	MXnTRW5ITVJ?
NCI-H358	NXjndVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYX5bXVNUUN3ME2zOVUvOzV4IN88US=>	M3XZR3NCVkeHUh?=
CW-2	NHjIUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rzc2lEPTB;M{W2MlUzQSEQvF2=	M{jaSHNCVkeHUh?=
COLO-678	NHPYco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTN3Nz64OlMh\|ryP	M4HHfXNCVkeHUh?=
NCI-H2126	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPOdmRMUUN3ME2zOVgvPTJzIN88US=>	NYP2SHVUW0GQR1XS
DMS-53	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTN3OD63NVEh\|ryP	M4PjdXNCVkeHUh?=
NCI-H1838	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4ryUWlEPTB;M{W5Mlk5PyEQvF2=	NEfkSJlUSU6JRWK=
SJSA-1	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnkW3hoUUN3ME2zOlAvQTN7IN88US=>	M{\uSXNCVkeHUh?=
ChaGo-K-1	Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XFTmlEPTB;M{[zMlkzPCEQvF2=	M3;KVnNCVkeHUh?=
IST-SL2	NIjhUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjsXll7UUN3ME2zO\|IvQTJ4IN88US=>	MkXVV2FPT0WU
U-266	NH\o[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nLdmlEPTB;M{ezMlE{OiEQvF2=	M1TaR3NCVkeHUh?=
P31-FUJ	NFzLV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M164fmlEPTB;M{e2Mlk3PCEQvF2=	NH;YWohUSU6JRWK=
HCC2157	M4PsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTN5OD6xOlEh\|ryP	M2X0[3NCVkeHUh?=
COR-L88	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzaNGlKSzVyPUO4N{43PzdizszN	MWrTRW5ITVJ?
NCI-H596	NV\3RZNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrK[3JKSzVyPUO4OU4{PCEQvF2=	Mn;UV2FPT0WU
GOTO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jFN2lEPTB;M{mwMlY1OSEQvF2=	NUjqTpViW0GQR1XS
NCI-H719	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjYfGU1UUN3ME2zPVEvQDl\|IN88US=>	MU\TRW5ITVJ?
MN-60	NEPFSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXufmE1UUN3ME2zPVMvQTR6IN88US=>	Mn3xV2FPT0WU
IST-SL1	NEnP[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTN7ND60NFYh\|ryP	M3TYOnNCVkeHUh?=
TE-6	NYXIc\|lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jyVGlEPTB;M{m3MlI2PCEQvF2=	NITsWnBUSU6JRWK=
SW962	M1W0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jyTmlEPTB;M{m4MlY6KM7:TR?=	MmfjV2FPT0WU
FADU	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTrZZc4UUN3ME20NFMvODh\|IN88US=>	MWDTRW5ITVJ?
ECC4	M3nF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH4TWM2OD12MEiuOFU5KM7:TR?=	M4DyUXNCVkeHUh?=
MES-SA	NUPYXoJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrsdHZzUUN3ME20NFkvQThizszN	Mn7uV2FPT0WU
NCI-H716	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTsN2pKUUN3ME20NVAvODd3IN88US=>	NFrjd5lUSU6JRWK=
GR-ST	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHKx[IFKSzVyPUSxNE41QTdizszN	MV\TRW5ITVJ?
KY821	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTRzND6wPFYh\|ryP	M3X1U3NCVkeHUh?=
NCI-H2141	NXroVGZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTR{ND6zPFgh\|ryP	NHzHfmlUSU6JRWK=
MDA-MB-134-VI	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4ns[WlEPTB;NEOxMlA{OyEQvF2=	Mn;oV2FPT0WU
RH-1	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3vTWM2OD12M{WuNFkh\|ryP	M17ET3NCVkeHUh?=
AM-38	M3zP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTR\|OD61OEDPxE1?	M1y3ZnNCVkeHUh?=
BL-70	M2XU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTR\|OT60Nlkh\|ryP	MnvTV2FPT0WU
COLO-684	NIK2OGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjMTWM2OD12NEiuPFg5KM7:TR?=	MXzTRW5ITVJ?
DMS-79	NIX6[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rQd2lEPTB;NES5MlY5KM7:TR?=	NVrNUnJOW0GQR1XS
EW-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTR3Mj64PFgh\|ryP	Mn;qV2FPT0WU
MS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rCZ2lEPTB;NEW0MlM5PSEQvF2=	MWDTRW5ITVJ?
A4-Fuk	NHf6eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEX2OIZKSzVyPUS1OE42ODdizszN	MlPDV2FPT0WU
TALL-1	NV\aOlFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTEPYFKSzVyPUS1OU4zQTdizszN	NHS1b\|lUSU6JRWK=
SCLC-21H	NFnKdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTD[WVXUUN3ME20OVUvPjl7IN88US=>	NXLHeZd4W0GQR1XS
KMS-12-PE	M3Tifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTR3Nj64NlIh\|ryP	M1LX[3NCVkeHUh?=
TE-441-T	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n3eGlEPTB;NEW3MlE5PiEQvF2=	NWK4W3h5W0GQR1XS
A3-KAW	NGTJTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonRTWM2OD12NkCuPFQyKM7:TR?=	MUfTRW5ITVJ?
NCI-H1092	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzNTWM2OD12NkOuPVQ{KM7:TR?=	NUe0SVVXW0GQR1XS
COR-L279	NHzBV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUX4b2VLUUN3ME20OlQvQDR5IN88US=>	NVr0U41QW0GQR1XS
NCI-SNU-5	NHz5dmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmO2TWM2OD12N{KuNlgh\|ryP	M3;2[3NCVkeHUh?=
JAR	MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTEeItKSzVyPUS3OE44QDhizszN	NH;RTHFUSU6JRWK=
NCI-H446	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTR5Nz6wPEDPxE1?	M17aTnNCVkeHUh?=
HDLM-2	MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{mxT2lEPTB;NEiwMlg3QSEQvF2=	NFfWTXFUSU6JRWK=
D-283MED	NUHOS2FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{H1N2lEPTB;NEi4MlkzPCEQvF2=	M3;RNXNCVkeHUh?=
NCI-H1395	NY\henA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTR6OT6wNFQh\|ryP	MkfvV2FPT0WU
RPMI-6666	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jEdmlEPTB;NEmxMlM6QCEQvF2=	NFPobZhUSU6JRWK=
CPC-N	M2i0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTVyMj6wOlMh\|ryP	MkXSV2FPT0WU
EC-GI-10	NYLLOWRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXm[Il5UUN3ME21NFIvOTZ7IN88US=>	NHG0dmJUSU6JRWK=
CA46	NXv1[YpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTVyND60NFch\|ryP	NVvZXIJLW0GQR1XS
EHEB	NIXsfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoriTWM2OD13MEeuNlA5KM7:TR?=	NW[4W4FUW0GQR1XS
RPMI-8402	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrsbWpKSzVyPUWxNE4xOjFizszN	M4fVWnNCVkeHUh?=
DU-4475	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTrTWM2OD13MUGuNVAyKM7:TR?=	M4jTVXNCVkeHUh?=
P12-ICHIKAWA	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvqTWM2OD13MUGuOFE3KM7:TR?=	MWPTRW5ITVJ?
NCI-H1694	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvpc3R3UUN3ME21NVIvPDN7IN88US=>	NX:0PXNLW0GQR1XS
NCI-H2171	NGezcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTVzMj63NFUh\|ryP	NV\SWmdFW0GQR1XS
Mo-T	NWq1N\|JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfh[457UUN3ME21NVUvOTF4IN88US=>	NXKwTHpbW0GQR1XS
HL-60	NV;yS\|FLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTJSFRuUUN3ME21NlIvQTJ2IN88US=>	NFLlS4tUSU6JRWK=
NCI-H1436	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH65d\|RKSzVyPUWyN{4xPjRizszN	MYfTRW5ITVJ?
NCI-H510A	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33S[GlEPTB;NUK0MlY6PiEQvF2=	NHLvUZVUSU6JRWK=
NCI-H2081	NGTFcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEO4S\|lKSzVyPUWyOU42OTNizszN	Ml3vV2FPT0WU
NB5	NHrxTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLhOFlKSzVyPUWyOk41OyEQvF2=	NWrrVJIzW0GQR1XS
NCI-H2227	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jJfmlEPTB;NUOwMlI2PCEQvF2=	NV72Vpg1W0GQR1XS
HSC-4	NXzERoxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;wZ\|BFUUN3ME21N\|kvOjl\|IN88US=>	MnrlV2FPT0WU
RL	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTV2Mj60OFIh\|ryP	NEPJUXVUSU6JRWK=
EVSA-T	MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHu1UotKSzVyPUW0N{43QDRizszN	NXj0fldbW0GQR1XS
NCI-H889	NFvuVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTV2Nz6yN{DPxE1?	MmX2V2FPT0WU
COLO-320-HSR	NWjtfnVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTV3MT6zOUDPxE1?	M4\xZ3NCVkeHUh?=
EW-11	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYH6VlFCUUN3ME21OVIvOzl7IN88US=>	MkSwV2FPT0WU
UACC-812	NWXifWFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTV3OT6zPVEh\|ryP	MoexV2FPT0WU
CAL-148	NF[zOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUD2e2V1UUN3ME21OlUvODh7IN88US=>	NV7pVGEzW0GQR1XS
K052	NF3MeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPZfFdKSzVyPUW3PU4zOTNizszN	M{fCd3NCVkeHUh?=
L-428	NFL1TVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D3SmlEPTB;NkCwMlY4OSEQvF2=	NEjWToVUSU6JRWK=
LP-1	M{XYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHETnpKSzVyPU[wN{42QDdizszN	NYfiU3NsW0GQR1XS
ML-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vWXGlEPTB;NkC2MlU4QSEQvF2=	M2TYNnNCVkeHUh?=
KARPAS-45	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLETWM2OD14MUiuNlIyKM7:TR?=	MnPrV2FPT0WU
HT	NHnYPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXyTWM2OD14MkKuO\|g2KM7:TR?=	M1X2[nNCVkeHUh?=
NCI-H226	M1HrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjXcplKSzVyPU[yPE4{PTNizszN	M2nnSXNCVkeHUh?=
L-363	MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzn[2JCUUN3ME22OFgvODZ2IN88US=>	NH72[5NUSU6JRWK=
IM-9	Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTZ3MT61OFEh\|ryP	Mmj4V2FPT0WU
TUR	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3yeXdKSzVyPU[3NU4{OjJizszN	NVSzUYhKW0GQR1XS
NCI-SNU-16	NHPP[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rtdGlEPTB;NkiwMlQ3OiEQvF2=	MYLTRW5ITVJ?
NCI-SNU-1	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HYcWlEPTB;NkmwMlE4OiEQvF2=	NFW1ZlBUSU6JRWK=
U-87-MG	NV\OeFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\qTWM2OD14OUSuOVg2KM7:TR?=	NGXuUmNUSU6JRWK=
KM-H2	Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Tl[GlEPTB;Nkm5MlA2QSEQvF2=	NEHYTZRUSU6JRWK=
DEL	NEG2e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjMZXN4UUN3ME23NFAvQDN6IN88US=>	NXj5PIxNW0GQR1XS
KARPAS-422	M1POUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLFUYZKSzVyPUe4PU4{OTVizszN	MnP6V2FPT0WU
BC-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRThyNT6yNFMh\|ryP	NIfadmZUSU6JRWK=
NCI-H1155	M4PYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLtTWM2OD16MUiuNFU6KM7:TR?=	MXfTRW5ITVJ?
NCI-H1581	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\YTWM2OD17MECuNlMyKM7:TR?=	NF\SRYVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / CD31 / VE-Cadherin / α-SMA / vimentin; PubMed: 30709379 J Exp Clin Cancer Res NCI-H460 cells were co-cultured with HUVECs in a 3D culture system, and then treated with 1 μM CHIR-99021, 10 μM or 20 μM Cisplatin, or a combination of both, for 24 h. Cells were harvested and immunoblotted with anti-cleaved PARP, anti-CD31, anti-VE-cadherin, anti-α-SMA, anti-vimentin, and anti-β-actin antibodies. CTNNB1; PubMed: 23993102 Cell Treatment with the GSK3β inhibitor CHIR-99021 led to increased levels of β-catenin in RKO and HT29 (non-mutant) cells. β-catenin; PubMed: 24165128 J Biol Chem HeLa cells were treated with 5 μm CHIR-99021 for the indicated times. The samples were analyzed by Western blot.	30709379 23993102 24165128
Growth inhibition assay	Cell viability; PubMed: 22039301 J Immunol HMC-1.2 cells were cultured in the absence or presence of GSK3β inhibitor (CHIR 99021, 3–30 µM) and viability cell count was assessed by trypan blue dye exclusion after 24 h, 48 h or 72 h. All data are presented as the mean ± SEM of three independent experiments conducted in triplicate. p < 0.05, p < 0.001* p < 0.0001*** vs vehicle treated control cells.	22039301
Immunofluorescence	SOX10 / EdU; PubMed: 28174705 Cell Mol Gastroenterol Hepatol Incorporation of EdU (white arrowheads) into SOX10+ ENS (enteric nervous system) cells with and without CHIR-99021. Oct3/4; PubMed: 24779365 BMC Res Notes Fluorescence micrographs showing the protein expression of Brachyury/Oct3/4 after a three day differentiation of ES-D3 cells with BIO (0.5 μM), SB-216763 (5 μM), CHIR-99021 (5 μM), or CHIR-98014 (1 μM). Nuclei were counterstained with DAPI (blue). The merge is shown in yellow. Original magnification 400x. Scale bar = 50 μm.	28174705 24779365

In vivo

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge. ^[1] Administration of CHIR-99021 significantly augments hematopoietic repopulation in recipient mice transplanted with mouse or human hematopoietic stem cells (HSCs), suggesting that GSK-3 is a specific modulator of HSC activity. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Cell-free kinase assays: Polypropylene 96-well plates are filled with 300 μL/well buffer (50 mM tris HCl, 10 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, 0.01% BSA, pH 7.5) containing 27 nM GSK-3α or 29 nM GSK-3β, and 0.5 μM biotin-CREB peptide substrate. Various concentrations of CHIR-99021 are added in 3.5 μL of DMSO, followed by 50 μL of ATP stock to yield a final concentration of 1 μM ATP in all cell-free assays. After incubation, triplicate 100-μL aliquots are transferred to Combiplate eight plates containing 100 μL/well 50 μM ATP and 20 mM EDTA. After 1 hour, the wells are rinsed five times with PBS, filled with 200 μL of scintillation fluid, sealed, left 30 minutes, and counted in a scintillation counter. All steps are performed at room temperature.
Cell Research: ^[3]	- Collapse Cell lines: INS-1E Concentrations: Dissolved in DMSO, final concentrations ~ 20 μM Incubation Time: 1, or 4 days Method: Cells are maintained for 24 hours in starvation medium (culture medium with only 5 mM glucose, 1% fetal calf serum). Then cells are exposed to various concentrations of CHIR-99021 for 1, or 4 days. Cell number is measured by staining of cellular DNA with CyQuant dye, which becomes fluorescent when bound to DNA. Fluorescence is measured after 30 minutes of incubation using the FLUOstar Optima reader. Cell replication is determined by BrdUrd incorporation. BrdUrd labeling solution is added to the medium for the last 4 hours before the cells are fixed using FixDenat solution and incubated with monoclonal anti-BrdUrd-POD antibodies. After substrate solution is added to each well, the light emission is measured in a microplate luminometer using the Analyst HT detection system. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female db/db mice or male ZDF rats with type 2 diabetes Formulation: Formulated as solutions in 20 mM citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose. Dosages: ~48 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL (185.33 mM)
	Ethanol	2 mg/mL (3.98 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	24mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Molecular Weight	501.8
Formula	C₂₂H₁₈Cl₂N_8.HCl
CAS No.	1797989-42-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I recently purchased CHIR 99021 to inject mice intraperitoneally. The data sheet says using 10% captisol for in vivo use. Is it for IP injection? Or do you have other solutions to suggest to use for in vivo IP injection of CHIR 99021?
Answer:
The formulation of 15% Captisol is for oral gavage, and S2924 CHIR-99021 (CT99021) HCl in it is a suspension. S2924 CHIR-99021 (CT99021) HCl can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 24mg/ml as a clear solution for IP injection.
Question 2:
How about the half-life of this compound? If it is necessary for daily treatment when the compound is used in long-term experiment?
Answer:
Please change the culture medium each day to add the new comound in it if the duration is more than 72h.
Question 3:
What is the difference between S2924 and S1263? Which one is better for differentiation?
Answer:
S1263 is the free base format of Chir-99021, while S2924 is the HCl salt format. They have the same biological activity but are slightly different in solubility.

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Selective GSK-3 Inhibitor

TWS119 : GSK-3β-selective, IC50 of 30 nM.
Most Potent GSK-3 Inhibitor

CHIR-98014 : GSK-3α, IC50=0.65 nM; GSK-3β, IC50=0.58 nM.
GSK-3 Inhibitor in Clinical Trial

Tideglusib : Phase II for Alzheimer's disease.
Newest GSK-3 Inhibitor

AZD1080 : Orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with K_i of 6.9 nM and 31 nM, respectively.

Related GSK-3 Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
LY2090314 ^New

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
TDZD-8 ^New

TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
TWS119

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology.
SB216763

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β.
Tideglusib

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
CHIR-98014

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
BIO

BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.

Features:The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
AR-A014418

AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and K_i of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.
IM-12

IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl

Cited by 111 Publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Related GSK-3 Products

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl

Cited by 111 Publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Related GSK-3 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)